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Definitions & Key Indicator Descriptions 
Acceptable storage conditions for medicines:  A wholesaler or outlet is considered to have 
acceptable storage conditions for medicines if it is in compliance with all the following three 
standards: (1) medicines are stored in a dry area; (2) medicines are protected from direct sunlight; 
and (3) medicines are not kept on the floor. 
Adult equivalent treatment dose (AETD):  The number of milligrams of an antimalarial treatment 
needed to treat a 60kg adult whereby all dosage types found (tablet, suspension, syrup, etc.) are 
converted regardless of their original presentation (whether for child or adult).  The number of 
mg/kg used to determine the dose is defined as what is recommended for a particular drug 
combination in the treatment guidelines for uncomplicated malaria in areas of low drug resistance 
issued by the WHO.  Where this does not exist, a product manufacturer’s treatment guidelines are 
consulted.  See Appendix 6.2 for additional details  
Antimalarial combination therapy:  The use of two or more classes of antimalarial drugs/molecules 
in the treatment of malaria that have independent modes of action. 
Antimalarial:  Any medicine recognized by the WHO for the treatment of malaria.  Medicines used 
solely for the prevention of malaria were excluded from analysis in this report. 
Artemisinin and its derivatives:  Artemisinin is a plant extract used in the treatment of malaria.  The 
most common derivatives of artemisinin used to treat malaria are artemether, artesunate, and 
dihydroartemisinin. 
Artemisinin monotherapy (AMT):  An antimalarial medicine that has a single active compound, 
where this active compound is artemisinin or one of its derivatives. 
Artemisinin-based Combination Therapy (ACT):  An antimalarial that combines artemisinin or one of 
its derivatives with an antimalarial or antimalarials of a different class.  Refer to combination therapy 
(below).   
Availability of any antimalarial or RDTs:  The proportion of wholesalers in which the specified 
antimalarial medicine or RDT was found on the day of the survey, based upon an audit conducted by 
the interviewer.  For indicators of availability, all wholesalers who were eligible to participate after 
screening (i.e. had any antimalarial or RDT in stock at present or at any point in the 3 months prior to 
interview) are included in the denominator. 
Booster sample:  A booster sample is an extra sample of units (or in this case outlets) of a type not 
adequately represented in the main survey, but which are of special interest.  The ACTwatch Outlet 
Survey included a booster sample of public health facilities in the entire district that includes the 
selected sub-district (ward), consisting of all of the public health facilities in the district that are not 
in the selected sub-district itself.  As there were 44 registered pharmacies in the country at the time 
of data collection, the booster sample for registered pharmacies included all those that were not 
already included in the selected sub-districts.  
Censused sub-district:  Wards where field teams conducted a full census of all outlets with the 
potential to sell antimalarials as part of the ACTwatch Outlet Survey. 
Combination therapy:  The use of two or more classes of antimalarial drugs/molecules in the 
treatment of malaria that have independent modes of action. 
Credit to consumers:  A wholesaler is considered to provide credit to consumers based on the 
response of the wholesaler.  
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Distribution chain:  The chain of businesses operating from the factory gate/port of entry down to 
the retail level.  Also sometimes referred to as downstream value chain.  In this report, the terms 
distribution chain and supply chain are used interchangeably.  More specifically, the ‘private 
commercial sector distribution chain’ refers to any type of public or private wholesaler who served 
private commercial outlets, as well as private commercial wholesalers who served public sector or 
NGO outlets so that any transactions between public, NGO and private commercial sectors are 
noted. 
Dosing/treatment regimen:  The posology or timing and number of doses of an antimalarial used to 
treat malaria. This schedule often varies by patient weight. 
First-line treatment:  The government recommended treatment for uncomplicated malaria.  
Zambia’s first-line treatment for Plasmodium falciparum malaria is artemether-lumefantrine, 
20mg/120mg. 
Inter-quartile range (IQR):  A descriptive statistic that provides a measure of the spread of the 
middle 50% of observations.  The lower bound value of the range is defined by the 25th percentile 
observation and the upper bound value is defined by the 75th percentile observation. 
Mark-up:  The difference between the price at which a product is purchased, and that at which it is 
sold.  Sometimes also referred to as margin.  In this report, the terms mark-up and margin are used 
interchangeably.  May be expressed in absolute or percent terms.  Because it is common for 
wholesalers to vary their prices with the volumes they sell, minimum, mid and maximum mark-ups 
were calculated in this report using price data collected from interviewees.  Key findings on price 
mark-ups at the wholesale level are reported using mid mark-up data.  As maximum and minimum 
selling prices were not collected at the retail level, only one set of absolute and percent retail mark-
ups is calculated. 
Absolute mark-up:  The absolute mark-up is calculated as the difference between the selling 
price and the purchase price per full-course adult equivalent treatment dose.  In this report, 
absolute mark-ups are reported in US dollars.  The average exchange rate during the data 
collection period for wholesale purchase prices (28 February to 6 May 2009) was 5693.71 
Zambia Kwacha (ZMK) to US$1; the average exchange rate during the collection period for 
retail purchase prices (14 April to 3 July 2009) was 5342.47 Zambia Kwacha (ZMK) to US$1 
(www.oanda.com). 
Percent mark-up:  The percentage mark-up is calculated as the difference between the 
selling price and the purchase price, divided by the purchase price. 
Maximum mark-up:  For wholesale level only, the absolute and percent maximum mark-ups 
are calculated as above using the difference between maximum wholesale selling price and 
the wholesale purchase price. 
Minimum mark-up:  For wholesale level only, the absolute and percent minimum mark-ups 
are calculated as above using the difference between minimum wholesale selling price and 
the wholesale purchase price. 
Mid mark-up:  For wholesale level only, the absolute and percent mid mark-ups are 
calculated as above using the difference between the average wholesale selling price (i.e. 
the mid-point between the maximum and minimum wholesale selling price) and wholesale 
purchase price.  
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Median:  A descriptive statistic given by the middle (or 50th percentile) value of an ordered set of 
values (or the average of the middle two in a set with an even number of values), which is an 
appropriate measure of central tendency of a skewed distribution of continuous data. 
Monotherapy:  An antimalarial medicine that has a single mode of action.  This may be a medicine 
with a single active compound or a synergistic combination of two compounds with related 
mechanisms of action.  
Non-artemisinin therapy (nAT):  An antimalarial treatment that does not contain artemisinin or any 
of its derivatives. 
Non-WHO prequalified ACTs:  ACTs that do not meet acceptable standards of quality, safety and 
efficacy as assessed by the WHO Prequalification of Medicines Programme, or have yet to be 
assessed as such.  (See WHO prequalified ACTs below)  
Oral artemisinin monotherapy:  Artemisinin or one of its derivatives in a dosage form with an oral 
route of administration.  These include tablets, suspensions, and syrups and exclude suppositories 
and injections.   
Outlet:  Any point of sale or provision of a commodity to an individual.  Outlets are not restricted to 
stationary points of sale and may include mobile units or individuals.  Refer to Appendix 6.1 for a 
description of the outlet types visited as part of the ACTwatch Outlet Survey.   
Purchase price:  The price paid by businesses (i.e. wholesalers or outlets) for their most recent 
purchase of an antimalarial product from their suppliers.  This is different from selling price (see 
below).  Prices are reported in terms of full adult equivalent treatment dose treatment.  Prices are 
shown in US dollars.  The average exchange rate during the data collection period for wholesale 
purchase prices (28 February to 6 May 2009) was 5693.71 Zambia Kwacha (ZMK) to US$1; the 
average exchange rate during the collection period for retail purchase prices (14 April to 3 July 2009) 
was 5342.47 Zambia Kwacha (ZMK) to US$1 (www.oanda.com). 
Rapid-Diagnostic Test (RDT) for malaria:  A test used to confirm the presence of malaria parasites in 
a patient’s bloodstream. 
Screening/Eligibility criteria:  The set of requirements that must be satisfied before the full 
questionnaire is administered. In the ACTwatch Supply Chain Survey, a wholesaler met the screening 
criteria if (1) they had any antimalarial or RDTs in stock at the time of the survey visit, or (2) they 
report having stocked either antimalarials or RDTs in the past three months. 
Second-line treatment:  The government recommended second-line treatment for uncomplicated 
malaria.  Zambia’s second-line treatment for Plasmodium falciparum malaria is quinine. 
Selling price:  The price paid by customers to purchase antimalarials.  For outlets, these customers 
are patients or caretakers; for wholesalers, these customers are other businesses or health facilities.  
Because it is common for wholesalers to vary their selling prices depending on the volumes 
purchased by the customer, data on maximum and minimum selling price charged for one unit by 
wholesalers were collected for each antimalarial product type in stock at the time of interview.   
Stock outs of ACT:  Reported in the affirmative as the percentage of interviewed wholesalers who 
reported to have always had at least one ACT in stock over the past 3 months.  All eligible (see 
Screening criteria above) wholesalers who were successfully interviewed were included in the 
denominator. 
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Sub-district (SD):  The primary sampling unit, or cluster, for the ACTwatch Outlet Survey is defined in 
Zambia as the ward, which consists of an agglomeration of Census Supervisory Areas that combined 
hosts a population size of approximately 10,000 to 15,000 inhabitants. 
Top selling antimalarial:  The antimalarial with the largest volume of adult equivalent treatment 
doses sold or distributed in the past week as reported by individual wholesalers.   
Volumes:  Volumes of antimalarials sold in the previous week are reported in terms of full-course 
adult equivalent treatment doses (or AETDs; see above for description). 
WHO prequalified ACTs:  ACTs that meet acceptable standards of quality, safety and efficacy as 
assessed by the WHO Prequalification of Medicines Programme.  This is a service provided by WHO 
to guide bulk medicine purchasing of international procurement agencies and countries for 
distribution in resource limited settings, often using funds for development aid (e.g. Global Fund 
grants).  More details on the list of prequalified medicines and the prequalification process may be 
found on the WHO website at: http://www.who.int/mediacentre/factsheets/fs278/en/index.html.  
Wholesalers:  Businesses that supply other businesses, which may include retailers or other 
wholesalers.  In this report, wholesalers are classified further into more specific categories defined 
by the type of businesses that they supply.  As some wholesalers will supply different types of 
businesses (e.g. both retail outlets and other wholesalers), these categories are not mutually 
exclusive and such wholesalers may appear in multiple categories.  These are defined below. 
Terminal wholesalers:  Wholesalers that supply retail outlets directly.  For example, 
wholesaler X is a terminal wholesaler if it supplies antimalarials to pharmacies and drug 
shops from which patients buy medicines.  Terminal wholesalers may supply retail outlets 
only, but may also supply other wholesalers. 
Intermediate-1 wholesalers:  Wholesalers that supply terminal wholesalers directly.  
Intermediate-1 wholesalers may supply terminal wholesalers only, but may also supply other 
types of wholesalers (such as other intermediate-1 wholesalers) and retail outlets. 
Intermediate-2 wholesalers:  Wholesalers that supply Intermediate-1 wholesalers directly.  
Intermediate-2 wholesalers may supply Intermediate-1 wholesalers only, but may also 
supply other types of wholesalers (such as terminal wholesalers) and retail outlets.  
Intermediate-3 wholesalers:  Wholesalers that supply Intermediate-2 wholesalers directly.  
Intermediate-3 wholesalers may supply Intermediate-2 wholesalers only, but may also 
supply other types of wholesalers (such as intermediate-1 or terminal wholesalers) and retail 
outlets.  
Wholesalers supplying retailers:  This is an analytical category specific to ACTwatch that 
groups together all wholesalers that may be categorised as a terminal wholesaler. 
Wholesalers supplying wholesalers:  This is an analytical category specific to ACTwatch that 
groups together all wholesalers that may be categorised as operating at an intermediate 
level of the supply chain (e.g. in this report, intermediate-1, intermediate-2 and 
intermediate-3 wholesalers).  
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Abbreviations 
ACT artemisinin-based combination therapy 
AETD adult equivalent treatment dose 
AL artemether lumefantrine  
AMFm Affordable Medicine Facility – malaria 
AMT artemisinin monotherapy 
ANC antenatal clinic 
AR artemether 
AS artesunate 
ASMQ artesunate and mefloquine 
CHW community health worker 
CQ chloroquine 
DfID UK Department for International Development 
DHA dihydroartemisinin 
DHA+PP dihydroartemisinin and piperaquine 
IMCI Integrated Management of Childhood Illness 
INT intermediate level (wholesaler of supply chain) 
IPT intermittent preventive treatment of malaria 
IQR inter-quartile range  
IRS indoor residual spraying 
ITN insecticide treated net 
LSHTM London School of Hygiene & Tropical Medicine  
MEC mutually-exclusive category of wholesalers 
MOH Ministry of Health 
MQ mefloquine 
MSL Medical Stores Limited 
nAT non-artemisinin therapy 
NGO non-governmental organisation 
NMCC National Malaria Control Centre 
OS ACTwatch Outlet Survey 
OTC over-the-counter 
Pf Plasmodium falciparum  
PMI US President’s Malaria Initiative 
POM prescription only medicine 
PPS probability proportional to size 
PRA Pharmaceutical Regulatory Authority 
PSI Population Services International  
RDT rapid diagnostic test 
SFH Society for Family Health/Zambia 
SP sulphadoxine pyrimethamine 
UN United Nations 
WHO World Health Organization  
WS wholesaler 
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Executive Summary 
Background 
In Zambia, as in many low-income countries, private commercial providers play an important role in 
the treatment of malaria.  To design effective interventions for improved access to accurate 
diagnosis and effective malaria treatment, there is a need to understand retailer behaviour and 
identify the factors that influence their stocking and pricing decisions.  Private commercial retailers 
are the last link in a chain of manufacturers, importers and wholesalers and their supply sources are 
likely to have an important influence on the price and quality of malaria treatment that consumers 
can access.  However, there is limited rigorous evidence on the structure and operation of the 
distribution chain for antimalarial drugs that serves the retail sector. 
 
The ACTwatch Supply Chain Study, one of the ACTwatch project components, aims to address this 
gap by conducting quantitative and qualitative studies on distribution chains for antimalarials in the 
ACTwatch countries (Cambodia, Uganda, Zambia, Nigeria, Benin, Madagascar and the Democratic 
Republic of Congo).  Other elements of ACTwatch include Retail Outlet and Household Surveys led by 
Population Services International (PSI).  This report presents the results of a cross-sectional survey of 
antimalarial drug wholesalers conducted in Zambia between February and May 2009. 
 
Methods 
The Supply Chain survey was implemented by the London School of Hygiene & Tropical Medicine 
(LSHTM), with support from the Society for Family Health/Zambia, following shortly after the 
ACTwatch Outlet Survey conducted by PSI.  Wholesalers operating at different levels of the supply 
chain that served a representative sample of Zambia’s malaria endemic areas were sampled through 
a bottom-up approach during which wholesalers were identified by their customers until the top of 
the chain was reached.  For this purpose, all 38 sub-districts from the ACTwatch Outlet Survey were 
included in the sample.  The sampling procedure used the list of the two top antimalarial wholesale 
sources (termed the terminal wholesalers) reported by each antimalarial retail outlet that 
participated in the Outlet Survey.  From these data a list of all terminal wholesalers mentioned was 
created.  All these terminal wholesalers were visited and invited to participate in the Supply Chain 
survey.  Wholesalers were eligible to participate if they met the following screening criteria: they 
had either an antimalarial or rapid diagnostic test (RDT) in stock at the time of interview, or they 
reported to have stocked either antimalarials or RDTs in the three months prior to interview.  During 
the interview, eligible wholesalers were also asked about their two top supply sources for 
antimalarials (termed the intermediate-1 wholesalers).  From these data, we created a list of all 
intermediate-1 wholesalers mentioned.  All these intermediate-1 wholesalers were visited and 
invited to participate in the Supply Chain survey, during which, as at previous levels, they were asked 
about their two top supply sources for antimalarials (termed the intermediate-2 wholesalers).  This 
process was repeated until the factory gate or port of entry was reached. 
 
The supply chain survey collected data on the structure of the private commercial sector supply 
chain; wholesaler characteristics and business practices; wholesale outlet licensing and inspection; 
wholesaler knowledge, qualifications and training; and wholesale availability, purchase prices and 
mark-ups for antimalarials and RDTs.  Retail outlets’ purchase prices and mark-ups for antimalarials 
collected during the Outlet Survey are also presented in this report as they form the last step of the 
supply chain before antimalarials reached patients/care takers and are therefore relevant to the 
study of the distribution chain. 
 
 
 2 
Results 
 
STRUCTURE OF THE SUPPLY CHAIN: A total of 57 antimalarial wholesalers were identified, and 43 were 
successfully interviewed. The maximum number of steps from manufacturers’ factory gate to retail outlets was 
5 with wholesalers operating across 4 overlapping levels: intermediate-3 (INT 3 WS), intermediate-2 (INT 2 
WS), intermediate-1 (INT 1 WS) and terminal (TERMINAL WS) levels (Figure 1).  However, less than a fifth of 
wholesalers were observed to operate at higher levels of the supply chain (i.e. supplying other wholesalers) 
while all wholesalers, regardless of supply chain level, supplied retailers directly. As a result, the supply chain is 
shaped as a pyramid with a particularly broad base. Each red dot on Figure 1 represents a mutually exclusive 
group of wholesalers and the array of arrows emanating from them describes the specific supply chain levels 
that each wholesaler group serves.  Their percentage share is attached to each group.  The dashed line in 
Figure 1 from manufacturer to retailer indicates that a few retailers purchased antimalarials directly from 
manufacturers although this was rare (2.5% of all suppliers mentioned by retailers were local drug 
manufacturers). 
 
Figure 1: Representation of the antimalarial 
distribution chain showing interactions between 
supply chain levels by mutually exclusive wholesaler 
category 
Note:  WS: wholesaler;  INT: intermediate 
Figure 2: Representation of the antimalarial 
distribution chain showing the overlap between 
wholesaler categories used for analysis 
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WHOLESALER CHARACTERISTICS:  Wholesalers had been in operation for a median of 9 years. Their businesses 
ranged in size, with wholesalers that supplied retailers being smaller than those supplying other wholesalers 
(median of 8 workers compared to 20 workers).  Nearly all wholesalers (98%) reported employing a member of 
staff with a health qualification, the most commonly reported being a pharmacist (91%) and a pharmacy 
technologist (79%).  Most wholesalers (86%) stored antimalarials appropriately (off the floor, in dry areas and 
out of direct sunlight), and a high proportion (98%) reported having been visited by a pharmaceutical inspector 
in the 12 months preceding the interview.  However, a smaller proportion of wholesalers (70%) were observed 
to have any up-to-date license from the Ministry of Health.  Two-thirds of wholesalers delivered antimalarial 
orders to their customers and more than 60% offered their customers credit facilities.   
 
AVAILABILITY OF ANTIMALARIALS & RDTS:  Only 7% of all wholesalers interviewed did not stock any 
antimalarial drugs at the time of interview, 72% had ACT in stock, and 67% stocked the ACT artemether+ 
lumefantrine (AL, the recommended first line treatment for uncomplicated Pf malaria in Zambia).  Availability 
of other antimalarial drugs was relatively high, with both oral and non-oral artemisinin monotherapies (AMT) 
being stocked by a third (33% and 35%) of all wholesalers and non-artemisinin therapies (nAT) by around three 
quarters (77%) of wholesalers. RDTs were stocked by less than a quarter (23%) of wholesalers. 
 
0% 20% 40% 60% 80% 100% 
…delivered antimalarials to customers 
…provided credit to antimalarial customers in the 
past 3 months 
…displayed an up-to-date license from the MOH 
…reported to have been visited by a pharmaceutical 
inspector in the past year 
…employed a member of staff with a health 
qualification 
…stored antimalarials in a dry area, out of direct 
sunlight & off the floor 
% of wholesalers that... 
AL 
0% 20% 40% 60% 80% 100% 
RDT 
nAT 
Non-oral AMT 
 Oral AMT 
ACT 
Any antimalarial 
% of wholesalers that stocked... 
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ANTIMALARIAL & RDT SALES VOLUMES:  The median number of adult equivalent treatment doses (AETDs) of 
antimalarials sold the week preceding the survey was 35.7 for ACT and 0 for AMT.  For nATs, the median 
number of AETDs sold was 320.9.  These figures reflect the fact that, among wholesalers who sold antimalarials 
the week before the survey (n=40), 53% reported the nAT sulphadoxine-pyrimethamine (SP) to be their top 
selling antimalarial, while only 25% reported AL, the government recommended first-line treatment, as their 
top selling antimalarial.  Wholesalers reported selling a median of 0 RDTs over the week preceding the survey. 
 
WHOLESALE PURCHASE PRICES:  The median wholesale purchase price (i.e. the price paid by wholesalers to 
purchase stock from their suppliers) per AETD varied across antimalarial drug categories.  Overall, AMTs had 
the highest median purchase price per AETD (US$8.90), followed by ACTs (US$ 5.09 per AETD) while nATs had a 
much lower median purchase price (US$ 0.27). Among wholesalers, the median purchase price for the 
government recommended first-line treatment, AL (US$ 5.29), was more than 30 times the wholesale purchase 
price of SP.  The wholesale purchase price for RDTs was similar to that of ACTs at US$ 5.19 per test. 
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WHOLESALE MARK-UPS FOR ANTIMALARIALS & RDTS:  The median mid percent mark-ups were similar across 
antimalarial categories: 27% on ACTs, 26% on AMTs and 25% on nATs.  Wholesale percent mark-ups were also 
fairly consistent across dosage forms, ranging from 24% for ACT tablets to 31% for AMT oral liquids. In absolute 
terms, mark-ups per AETD were the highest on AMT (US$ 2.20), followed by ACT (US$ 1.58) and nAT (US$ 
0.14), which reflected differences in purchase prices across drug categories.  For similar reasons, variation in 
absolute mark-up was also seen across dosage forms, with injectables tending to have the highest absolute 
mark-ups, followed by oral liquids and then tablets.  For example, the median mid absolute mark-up on AMT 
injectables was US$ 4.22, compared to US$ 1.47 for oral liquids, and US$ 1.12 for tablets.  For AL, median mid 
percent mark-up was 24% (corresponding to a median mid absolute mark-up of US$ 1.32 per AETD), compared 
to 24% for SP (corresponding to a median mid absolute mark-up of US$ 0.03 per AETD).  For RDTs, the median 
wholesale percent mark-up was 48%, equivalent to US$ 2.38 in absolute terms. 
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RETAIL PURCHASE PRICES:  Similar to the wholesale level, median retail purchase prices (i.e. the price paid by retailers to purchase stock from their suppliers) 
per AETD varied across antimalarial drug categories.  In general, AMTs were observed to have the highest median retail purchase prices per AETD (ranging 
from US$ 4.49 at drug stores to US$ 10.11 at private health facilities), followed by ACTs (ranging from US$ 0.94 at grocery stores to US$ 5.62 at pharmacies), 
and nATs (ranging from US$ 0.16 at grocery stores to US$ 1.12 at pharmacies).  Pharmacies and private health facilities tended to have paid higher purchase 
prices for antimalarials compared to drug stores and grocery stores. This reflected pharmacies’ and private health facilities’ tendency to stock more 
antimalarials in injection and suspension forms, paediatric formulations, and ‘premium priced’ products (i.e. products strategically priced toward the high 
end of the price range to attract status-conscious consumers; an example is halofantrine). This, in turn, may reflect the preferences of customers at 
pharmacies and private health facilities that may differ from those at drugs stores and grocery stores. 
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RETAIL MARK-UPS FOR ANTIMALARIALS:  Median mid percent mark-ups among retailers tended to be higher than those observed among wholesalers. They 
also varied considerably across outlet type and antimalarial category.  For ACTs, the median mark-up ranged between 43% in pharmacies and 200% at drug 
stores; on AMT between 33% at drug stores and 201% at private health facilities; and on nAT between 82% at pharmacies and 114% at drug stores.  Mark-
ups above 100% were commonly observed, particularly among nATs.  Variation in absolute mark-ups was also observed across antimalarial categories and 
across outlet types, corresponding closely with variations in purchase price: mark-ups on ACTs ranged between US$ 1.40 and US$ 4.12; on AMT between US$ 
1.50 and US$ 25.16; and on nAT between US$ 0.17 and US$ 0.67. For AL, the median mid percent mark-up was 43% (US$ 2.99 absolute mark-up) at 
pharmacies, 71% (US$ 4.31) at private health facilities, 150% (US$ 1.40) at grocery stores, and 200% (US$ 2.67) at drug stores. 
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Conclusion 
This report presents a number of important new insights into the market for antimalarial drugs in Zambia.  
The distribution chain had a pyramid shape, with a relatively broad base and narrow top.  While we 
observed wholesalers to operate over 4 overlapping levels, all wholesalers identified were observed to 
supply retailers directly and a high proportion of wholesalers (42%) identified a manufacturer as one of their 
top antimalarial suppliers.  As such, it is likely that most antimalarials in the private sector pass through a 2- 
or 3-step supply chain between manufacturer to retailer.  ACTs, and in particular artemether-lumefantrine, 
the recommended first-line treatment for uncomplicated malaria, were observed to be available in about 
70% of wholesalers; however, wholesale purchase prices for ACTs are high and are many times more 
expensive than other common antimalarials, such as SP.  This may have contributed to our observation that 
SP was the most commonly reported top-selling antimalarial by wholesalers (50%), while only 28% of 
wholesalers reported AL as their top-selling antimalarial.  With respect to oral AMTs, despite the ban on 
their sale since October 2008, one third (33%) of all wholesalers continued to stock oral AMTs; however, 
their sales volumes during the week prior to the survey were observed to be very low.  Wholesale percent 
mark-ups were observed to be consistent both across antimalarial categories and across dosage forms, and 
tended to be lower than retail-level percent mark-ups on antimalarials. For RDTs, their wholesale purchase 
prices were also high and they were not widely available among wholesalers.  
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1. Introduction & Objectives 
Alongside the public and non-profit sectors, private commercial providers are important sources of malaria 
treatment in Zambia.  To design effective interventions for improved access to accurate diagnosis and 
effective malaria treatment, there is a need to understand retailers' behaviour and identify the factors that 
influence their stocking and pricing decisions.  Private commercial retailers are the last link in a chain of 
manufacturers, importers and wholesalers, and their supply sources are likely to have an important 
influence on the price and quality of malaria treatment that consumers can access.  However, there is 
limited rigorous evidence on the structure and operation of the distribution chain for antimalarial drugs that 
serves the retail sector. 
 
This study aims to address this gap and constitutes an integral part of the ACTwatch project, a multi-country 
programme of research being conducted in Zambia, Cambodia, Uganda, Nigeria, Benin, Madagascar and the 
Democratic Republic of Congo.  The overall goal of ACTwatch is to generate and disseminate evidence to 
policy makers on artemisinin-based combination therapy (ACT) availability and price in order to inform the 
development of policies designed to increase rates of access to effective malaria treatment.  Along with the 
Supply Chain Study, the ACTwatch project also includes Outlet and Household Surveys led by Population 
Services International (PSI). 
 
The objective of the Supply Chain component of ACTwatch is to document and analyse the supply chain for 
antimalarials and rapid diagnostic tests (RDTs) for malaria using quantitative (structured survey) and 
qualitative (in-depth interviews) methods for studying providers operating at each level of the chain.  This 
report presents the results of the structured survey of antimalarial drug wholesalers conducted in Zambia 
between February and May 2009.  In order to provide a complete description of the supply chain for 
antimalarial drugs, the report also presents retail-level data on antimalarial purchase prices and mark-ups 
that were collected during the ACTwatch Outlet Survey by the Society for Family Health/Zambia between 
April and July 2009. 
2. Country Background  
Economic Profile 
Zambia is a landlocked country located in Southern Africa sharing borders with Angola, Democratic Republic 
of Congo, Malawi, Mozambique, Namibia, Tanzania, and Zimbabwe.  The population is approximately 12 
million people of which an estimated 65% live in rural areas.  In recent years, Zambia has experienced 
relatively high economic growth, with a gross domestic product (GDP) growth rate ranging between 5.7% 
and 7.0% from 2008 to 2010, and per capita GDP estimated at US$ 1,500 in 2010. [1]  Historically, the 
country’s economy has relied heavily on the copper mining industry; however, the government has made 
efforts to diversify by promoting agriculture, tourism, gemstone mining and hydro-power, relying on a 
private-sector-led model of economic development. [2]  Most recently in 2009, the government launched 
the second phase of the Private Sector Development Reform Programme which aims to accelerate and 
broaden private sector growth. [3]  Despite this, 85% of the labour force was engaged in agriculture in 2004, 
while only 6% were employed in the industrial sector and 9% in the service sector; 50% of the estimated 5.5 
million labour force were unemployed; and a majority of the population was estimated to live below the 
poverty line. [1] 
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Pharmaceutical Sector 
The sector is regulated by the Pharmaceutical Regulatory Authority of Zambia (PRA), which is responsible for 
the registration of all products prior to importation and sale, the licensing of pharmaceutical manufacturers, 
importers, wholesalers and retail pharmacies, and post-marketing surveillance. [4]  With only limited 
domestic pharmaceutical manufacturing capacity, the country relies heavily on the importation of 
medicines.  The public and mission pharmaceutical sectors both follow a highly centralised model for 
medicine procurement and distribution, while less is known about the structure and operations of the 
private pharmaceutical sector.  All private pharmaceutical importers, wholesalers, and retail pharmacies are 
required to employ a pharmacist registered with Medical Council of Zambia.  The PRA issues several licenses 
for the importation, wholesale and pharmacy retail of medicines.  Hospital pharmacies also require a specific 
license from the PRA, while the Medical Council of Zambia maintains a register of private clinics.  Drug stores 
registered with local governments, rather than licensed by the PRA, and are not required to employ a 
pharmacist.  These retails outlets are common and should only dispense over-the-counter medicines, but in 
practice also dispense prescription only medicines.  Other common sources of over-the-counter medicines in 
the private sector include grocery stores and several other types of general shops that focus on the sale of 
fast moving consumer goods.  Medicine prices or mark-ups in Zambia are not regulated.  
 
Health System 
Zambia’s health system is dominated by the public sector:  of the 1,327 healthcare facilities in Zambia, 85% 
percent are government-run facilities, ranging from health posts to large tertiary hospitals; while 9% are 
private sector facilities and 6% are mission facilities.  Geographic access to healthcare varies widely with 99% 
of urban households residing within five kilometres of a health facility, compared to 50% of rural 
households. [5]  Since 1993, government health facilities charge user fees for the majority of services, but 
fees were removed for publicly provided primary health care services in rural areas in 2006, which 
dramatically increased health service use in these areas following implementation. [6]  By 2008, it was 
estimated that the public sector provided care for over 80% of the population, with the non-profit and 
private sectors providing the remaining services. [6]  Despite these improvements in access to health 
services, there is still considerable room for improvement in national health indicators.  Life expectancy in 
2006 for both men and women was below 45 years and nearly one in six children die before reaching their 
fifth birthday, with malaria acting as a key driver of child mortality. [7]  In 2007, the country had an 
estimated 4.3 million clinically diagnosed cases of malaria, accounting for 36% of outpatient visits, 48% of 
the disease burden among children below five years of age, and up to 20% of maternal deaths. [8] 
 
Malaria Epidemiology and Control Strategies 
Malaria is endemic throughout Zambia.  Between 90% and 100% of the population are at risk for infection, 
with peaks occurring during the rainy season between November and April.  Despite widespread endemicity, 
certain areas of the country can be characterised as hyperendemic, mesoendemic, or epidemic prone.  The 
predominant parasite is Plasmodium falciparum (Pf) which accounts for the vast majority of infections. [9]  
The National Malaria Control Strategy identifies pregnant women and children under five as the population 
groups most at risk.  Key malaria prevention and treatment interventions include distribution of insecticide 
treated nets (ITNs) through campaigns, antenatal clinics (ANCs) and the commercial sector; indoor residual 
spraying (IRS) in urban and peri-urban areas; intermittent preventive treatment (IPT) for pregnant women 
through ANCs; and administration of ACTs through health facilities with increasing focus on confirmed 
diagnosis using microscopy or RDTs. [10]  A recent study that examined the progress and impact of the 
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national control strategy showed that, by 2008, 68% of households had at list one ITN or had received IRS 
and a similar proportion of pregnant women (66%) received 2+ doses of IPT. [11] 
 
Malaria Financing 
Malaria prevention and treatment in Zambia is largely supported by international donors.  As noted above, 
the key malaria partners include the Global Fund, the World Bank, the US President’s Malaria Initiative 
(PMI), UNITAID, and DfID.  The NMCC received US$ 39.2 million during the Global Fund Round 1, US$ 42.7 
million during Round 4, and US$ 17.7 million during Round 7 for a range of malaria prevention and 
treatment interventions.  The World Bank provided US$ 20 million through its 2005-2010 Malaria Health 
Booster program for health systems strengthening and small community grants. PMI awarded US$ 9.5 
million in 2007 and US$ 14.8 million in 2008.  UNITAID has provided support for the procurement of 1.1 
million ACT doses since 2007. 
 
National Treatment Policy 
In 2003, Zambia became the first African country to adopt the use of ACTs over chloroquine, selecting 
artemether lumefantrine (AL) as the first-line treatment, sulphadoxine-pyrimethamine (SP) as the alternative 
first line treatment in pregnant women and children less than 5kg, and oral quinine as the second-line 
treatment in cases of failure of first-line drugs in all age groups (Table 1).  Severe malaria is treated with 
quinine.  In Zambia, ACTs are classified as prescription-only medications and are therefore not sold legally 
through unlicensed private sector providers; their availability has therefore remained largely restricted to 
the public sector, registered pharmacies and private facilities. [8, 12, 13]  In 2003, the Ministry of Health 
placed a ban on the use of oral artemisinin monotherapies (AMTs) for the treatment of uncomplicated 
malaria to delay the emergence of resistance to ACTs [14]; however the results from the ACTwatch Outlet 
Survey in 2009 indicated that oral AMTs were still widely available in the private sector, particularly among 
registered pharmacies and private health facilities. [12]  The National Malaria Control Centre (NMCC) 
recommends parasitological diagnosis for all patients with suspected malaria at hospitals and health centres 
with laboratory facilities.  Clinical diagnosis is recommended where laboratory facilities are not available.  
Children under five years of age are treated based on laboratory diagnosis in health facilities where 
available, and otherwise are evaluated and treated according to the algorithm of the Integrated 
Management of Childhood Illness (IMCI). 
 
Table2.1: National Malaria Treatment Guidelines 
Condition Recommendation 
Dosage 
form 
Strength 
Uncomplicated malaria Artemether-Lumefantrine Tablet 20mg/120mg 
Pregnant women & children under 5kg – 
uncomplicated 
Sulphadoxine Pyrimethamine Tablet 500mg/25mg 
Treatment failure Quinine (oral) Tablet 200mg or 300mg 
Severe & complicated malaria Quinine (injection) Ampoule 150mg/ml 
 
Antimalarial Treatment Distribution and Delivery 
As part of Zambia’s implementation of its Global Fund grants, ACT treatment has been procured and is 
dispensed in the public sector free of charge.  AL has been distributed to health facilities since the end of 
2004.  In order to ensure rational use of these drugs, the Global Fund also supported procurement and 
 12 
 
distribution of RDTs and microscopes, and training of health workers in their use.  A round 1 grant from the 
Global Fund provided sufficient ACTs to cover 28 out of the 72 districts in Zambia between 2003 and 2009, 
and national scale up commenced with resources from a round 4 grant from 2005, via health facilities, 
community health workers (CHWs) and pharmacies.  As of November 2008, 11 districts had also started 
community-based treatment of malaria with ACTs. 
 
ACT delivery in Zambia is also supported by financing from other donors.  The World Bank Malaria Booster 
project provides health system strengthening to improve service delivery, small grants for community-level 
malaria control, and funding to the Ministry of Health (MOH)/NMCC; UNITAID has supplied 1.1 million ACT 
doses for community distribution; and the UK Department for International Development (DfID) has 
provided funds to redesign Zambia’s public sector supply chain distribution system in collaboration with John 
Snow International/DELIVER and the World Bank. 
 
According to the ACTwatch Outlet Survey, public health facilities, private health facilities, pharmacies, and 
drug shops were the most common outlets carrying any type of antimalarial in Zambia in 2009. [12]  ACTs 
were rarely available in unlicensed private sector providers (e.g. around 6% in drug stores, and less than 1% 
in other types of providers). [12]  The majority of antimalarial treatments are obtained through public 
facilities; the ACTwatch Household Survey also conducted in 2009 showed that 85% all antimalarial 
treatment for children were acquired from the public sector; however 7.5% of treatment for malaria was 
obtained through private sector sources such as pharmacies, drug shops and private health facilities. [13] 
 
3. Methods 
3.1. Scope of the supply chain survey 
The Supply Chain structured survey was conducted amongst wholesalers who operate in the private 
commercial distribution chain that serve the antimalarial drug retailers described in the ACTwatch Outlet 
Survey report. [12]  The term ‘private commercial sector distribution chain’ refers to any type of supplier 
(public or private) who serve private commercial outlets as well as private suppliers who serve public and 
NGO outlets.  This allows any transactions between public, NGO and private commercial sectors to be noted.  
Public suppliers of public outlets are, however, not included because much more is already known about the 
structure of the public sector chain compared to that of the private commercial sector.  The focus is on 
suppliers who operate from the point where commodities leave the factory gate or port of entry down to 
those directly supplying retailers.  See Figure 3.1 for a representation of the wholesale supplier interactions 
that are captured by the Supply Chain survey. 
 
The supply chain survey explored the distribution chain for antimalarials, comprising artemisinin-
combination therapy or ACT (e.g. artesunate and mefloquine), artemisinin monotherapies or AMT (e.g. 
artesunate, artemether) and non- artemisinin monotherapies or nAT (e.g. chloroquine, quinine).  It 
considered all formulations (tablets, syrups, injectables etc), whether they are used for inpatient or 
outpatient care and it excluded complementary products, such as drips, water and syringes.  It also explored 
the availability, sales volumes and mark-ups on RDTs sold in the distribution chain under study, but excluded 
microscopy services.  The latter were excluded because of the wide range of different products used in 
providing microscopy services, and the problems in distinguishing those used for malaria diagnosis from 
those with other purposes. 
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The structured survey was cross-sectional and collected data on the structure of the private commercial 
sector supply chain for antimalarial drugs; wholesaler characteristics and business practices; wholesale 
outlet licensing and inspection; wholesaler knowledge, qualifications and training; and wholesale availability, 
purchase prices and mark-ups for antimalarials and RDTs.  In order to provide a complete description of the 
supply chain for antimalarial drugs, the report also presents retail-level data on antimalarial purchase prices 
and mark-ups that were collected during the ACTwatch Outlet Survey by PSI/Society for Family Health-
Zambia (SFH) between April and July 2009. 
 
Figure 3.1:  Antimalarial wholesale supplier interactions captured by the Supply Chain Study 
 
3.2. Sampling & data collection procedures 
3.2.1. Overview of sampling and data collection during the ACTwatch Outlet Survey 
For the purpose of the ACTwatch study, Zambia was divided into 2 strata: one stratum each for rural and 
urban areas.  In each stratum, 19 sub-districts were randomly sampled using a probability proportional to 
size (PPS) approach through which more populated sub-districts had a higher chance of being selected.  Sub-
districts were defined as the existing electoral wards in 2000.  In each sub-district, a census of all public and 
private outlets that had the potential to sell or distribute antimalarials was conducted and outlets that 
stocked antimalarials at the time of the survey or in the past 3 months were invited to participate in the 
Outlet Survey.  In order to estimate antimalarial availability and price across different outlet types, this 
sample was supplemented by a booster sample that included all public sector outlets operating in the district 
that includes the sampled sub-district or ward, and all 44 registered pharmacies operating in Zambia at the 
time of data collection.1  The use of a booster sample is a common procedure across all ACTwatch outlet 
surveys to ensure adequate representation of relatively rare but important antimalarial provider types.  
Public sector outlets (e.g. health posts, health centres, hospitals) that stocked antimalarials were identified 
through a census in the relevant districts.   
 
                                                          
1
 Due to logistical limitations, only 39 of the 44 registered pharmacies operating in Zambia at the time of data collection were 
included in the first round of the ACTwatch Outlet Survey.  
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The Outlet Survey was conducted in the sampled sub-districts and booster districts by PSI/SFH Zambia 
between April and July 2009.  The Outlet Survey collected data on antimalarial drug availability, sales 
volumes and selling prices, retail outlet and shopkeeper characteristics (antimalarials stocked, other drugs 
stocked, number of staff, education, health-related qualifications, registration status, GPS co-ordinates) as 
well as other areas of importance for the Supply Chain Survey, including each retailer’s two top supply 
sources for antimalarials (name, location, type of provider, whether they distribute, collect or both) and 
antimalarial wholesale purchase prices. 
 
3.2.2. Sampling and data collection procedures for the ACTwatch Supply Chain survey 
The Supply Chain survey was implemented by LSHTM, with support from SFH Zambia, shortly after the 
Outlet Survey, from February to May 2009.  All 38 of the Outlet Survey’s sampled sub-districts were used to 
create a list of antimalarial wholesale sources mentioned by retailers as their two top antimalarial wholesale 
sources (termed the “terminal wholesalers”).2,  All these terminal wholesalers were visited and invited to 
participate in the Supply Chain survey.  Wholesalers were eligible to participate if they met the following 
screening criteria: they had either an antimalarial or RDT in stock at the time of interview, or they reported 
having stocked either antimalarials or RDTs in the three months prior to interview.  During the interview, 
eligible wholesalers were also asked about their top two supply sources for antimalarials (termed the 
“intermediate-1” wholesalers).  From these data, we created a list of all intermediate-1 wholesalers 
mentioned.  All these intermediate-1 wholesalers were visited and invited to participate in the Supply Chain 
survey, during which, as at previous levels, they were asked about their top two supply sources for 
antimalarials (termed the “intermediate-2” wholesalers).  This process was repeated until the factory gate or 
port of entry was reached. 3 
 
The Supply Chain Survey used an information sheet, a consent form, a provider questionnaire, and 
antimalarial and RDT inventory sheets.  All data collection tools were provided in English, piloted by trained 
data collectors, and further revisions were made to adapt the tools to the Zambian context.  Before each 
interview, trained interviewers sought to speak with the most knowledgeable person about the 
antimalarial/RDT wholesale business.  They informed respondents about the study by providing the 
information sheet in English.  Interviewers stated their name, the institutions involved, aims of the study, 
nature of questions to be asked and length of the interview.  Each respondent was given the opportunity to 
ask questions at any time before, during and after the interview, and received the contact details of the local 
research coordinator.  Interviewers then invited respondents to participate in the study and obtained oral 
consent, witnessed by a member of the research team.  Interviewers emphasized that individual information 
was confidential and that no information would be passed on to regulatory authorities or competitors. 
 
The provider questionnaire was used for collecting data on wholesalers’ characteristics and operations and 
on their top two supply sources for antimalarials and RDTs.  Inventory sheets were used for collecting data 
for each antimalarial/RDT stocked, on brand name, generic name and strengths (for antimalarials), package 
                                                          
2
 Supply sources for outlets that were sampled as part of the outlet survey booster sample were excluded.  
3
 There may be horizontal trading within the supply chain, for example if a terminal wholesaler purchases their antimalarial drugs 
from another wholesaler who has also been identified from the outlet survey as a terminal wholesaler.  Where these relationships 
were identified at the wholesale level the supply chain survey was not administered again to this wholesaler, though the relationship 
was noted and accounted for in the analysis.  However, in the case where horizontal trading is identified at the retail outlet level (for 
example, a retailer identifies another retailer as the source of their antimalarials), the supply chain survey was administered to the 
source of supply, even if they have already filled in the outlet survey instrument, because the questions asked were different.   
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type and size, recall of volumes sold over the week before the survey, recall of last purchase value and 
selling and purchase prices.  
 
The Supply Chain component of the ACTwatch study received ethical approval from the University of Zambia 
Biomedical Research Ethics Committee and the LSHTM ethics review committee. 
 
3.3. Data analysis 
3.3.1. Classification of outlets 
A challenge in the analysis of wholesalers is their classification into sub-groups, as in practice many operate 
at several levels of the distribution chain.  We have taken 2 approaches:  
 
 To describe the structure of the chain, wholesalers were classified into mutually-exclusive categories 
(MECs) defined by the levels they supplied.  For example, wholesalers supplying retailers only, 
wholesalers supplying retailers and terminal wholesalers only, and wholesalers supplying intermediate 
and terminal wholesalers only. 
 For analytical purposes, wholesalers were grouped into 2 broader and overlapping categories: one 
including wholesalers supplying retailers and one for wholesalers supplying wholesalers.  Some 
wholesalers may therefore be included in both analytical categories.  This second approach for 
classifying wholesalers addresses the issues of individual MECs including very few wholesalers.  
Furthermore, this approach reflects the actual operations of the distribution chain. 
In order to get a complete picture of the distribution chain for antimalarial drugs, data relevant to the retail 
level are also presented for 5 mutually exclusive categories of retailers:  pharmacies, private health facilities, 
drug stores, grocery stores, and public health facilities.  See appendix 6.1 for descriptions of the type of 
retailers included in these categories. 
 
3.3.2. Calculation of sales volumes 
Antimalarial volumes and price data are reported for 3 dosage forms4, namely tablets, oral liquids and 
injectables5 and 3 antimalarial categories6 namely artemisinin-based combination therapy (ACT), artemisinin 
monotherapies (AMT) and non-artemisinin therapies (nAT).  ACTs were further sub-divided into WHO-
prequalified ACT and non-WHO-prequalified ACT. 
 
Antimalarial volumes were calculated on the basis of an adult equivalent treatment dose (AETD).  An AETD 
was defined as the number of milligrams (mg) of an antimalarial drug needed to treat a 60 kg adult (refer to 
Appendix 6.2 for data used during calculation of AETD).  The number of mg/kg used to calculate one AETD 
was defined as what was, at the time of the study, recommended for a particular drug combination in the 
treatment guidelines for uncomplicated malaria in areas of low drug resistance issued by the WHO.  Where 
WHO treatment guidelines did not exist, AETDs were based on product manufacturers’ treatment guidelines.  
                                                          
4
 Other dosage forms, such as suppositories and granules, are not mentioned in this report because no suppositories and only 1 
granule product were found during the ACTwatch surveys conducted in Zambia 
5
 Liquid and powder injectables form a single category.  The prevalence of powder injectables was very low (never found at 
wholesale level, 2 observations at retail level). 
6
 Antimalarial drugs intended for prophylaxis only and drug combinations not used to treat malaria but that contain an ingredient 
with antimalarial action were excluded from analysis.  
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In the case of ACTs as the treatment consists of 2 or more active antimalarial ingredients packaged together 
(either co-formulated or co-blistered), the strength of the artemisinin-based component was used as the 
principal ingredient for the AETD calculations.  Information collected on both the medicine strength and unit 
size, as listed on the product packaging, was then used to calculate the number of AETDs contained in each 
unit.  The median number of antimalarial doses reported to have been sold during the week preceding the 
survey was estimated for each antimalarial category for each wholesaler category.  Estimates were 
calculated by first summing the number of AETDs sold for the different antimalarial categories at each 
wholesale outlet and then by taking the median across the wholesaler category. Similar estimates were 
made for RDT sales volumes in each wholesaler category. 
 
For wholesale outlets that stocked antimalarials/RDTs and for which some or all sales volumes were missing, 
missing values were imputed using the STATA 11 command mi impute pmm7.  For wholesale outlets with no 
antimalarials of a given category in stock at the time of the survey, sales volumes over the past week were 
assumed to be null.  For wholesale outlets without information about the type of antimalarials stocked 
(because of refusals to participate in the study or to provide information on the type of antimalarials stocked 
or because of interrupted interviews), sales volumes were treated as missing.  In the case of an outlet not 
stocking antimalarials, sales volumes were set to zero. 
 
3.3.3. Calculation of purchase prices and mark-ups 
Wholesale purchase prices and mark ups were calculated using data collected during the ACTwatch Supply 
Chain Survey.  Because it is common for wholesalers to vary their prices with the volumes they sell, 
minimum, mid-point and maximum mark-ups were calculated using data on maximum and minimum selling 
price charged for one unit by wholesalers.  The wholesale maximum percentage mark-up was calculated as 
the difference between the highest wholesale selling price (that is the price of the minimum volume sold 
wholesale) and the wholesale purchase price, divided by the wholesale purchase price.  The wholesale 
minimum mark-up was calculated as the difference between lowest wholesale selling price (that is the 
minimum price charged for wholesale sales) and wholesale purchase price, divided by wholesale purchase 
price.  The wholesale percent mid mark up was calculated as:  
 
[[[(highest selling price)+(lowest selling price)]/2]- (wholesale purchase price)]/(wholesale purchase price) 
 
Retail purchase prices and mark-ups were calculated using price data collected during the ACTwatch Outlet 
Survey.  When calculating summary estimates for purchase prices and mark-ups, there was a need to weight 
outlet survey data to allow for (a) the difference in sampling probabilities due to variation in the size of 
strata, (b) the oversampling for the booster, and (c) the sampling strategy which involves a census of retail 
outlets in the sub-districts of varying size selected using PPS. Stratum-specific weights were calculated for 
each sub-district sampled.  Appendix 6.3 provides a detailed description of the calculations performed and 
weights used. 
 
Retail percentage mark-ups were calculated for each product as the difference between selling price and 
purchase price, divided by purchase price.  For both retail and wholesale observations, absolute mark-ups 
                                                          
7
 A technique used for imputing missing values of one continuous variable whose distribution is skewed.  Missing values (e.g. in the 
case of an outlet stocking antimalarials and with the antimalarial type identified in the audit sheet but for which sales volume data 
were missing) were imputed using covariates related to provider/outlet and product characteristics.  Five imputations were 
conducted and their mean imputed to the missing values.   
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were calculated for each product as selling price minus purchase price.  Data were collected in local 
currencies and converted to their US$ equivalent using the average interbank rate for the duration of the 
fieldwork period.8 
 
3.3.4. Summary measures 
Indicators are reported using median and inter-quartile range (IQR), which are relevant for describing 
distributions likely to be skewed.  Given that for the analytical purpose, wholesalers were classified into 
overlapping categories (i.e. wholesalers supplying retailers and wholesalers supplying wholesalers), it was 
not possible to conduct statistical tests of difference between the 2 groups.  
4. Results 
4.1. Overview of the Supply Chain survey sample 
A total of 315 supply sources were listed by retailers censused in the 38 selected Outlet Survey sub-districts, 
of which 8 (2.5%) referred to local manufacturers, and 37 (12%) were obvious duplicates (a source named by 
more than one outlet).  For 10 (3%) sources, there was too little information on either business name or 
location for identification, so these sources were removed.  Uncertainties around other suppliers’ business 
name or location were clarified by calling suppliers, and in the absence of contact numbers, advice on 
location was sought from local informants, including SFH staff members and data collectors who had 
participated in the Outlet Survey data collection.  This process identified 211 (67%) additional duplicates, 
leaving a total of 57 suppliers to form the sample of terminal wholesalers.  Out of the 57 terminal level 
wholesalers identified, 9 were ineligible to participate and 1 could not be located.  Among those eligible 
wholesalers invited to participate, 1 refused, 2 were not interviewed as a suitable respondent was not 
available following 3 visits, and 1 stopped the interview to indicate that they refer all wholesale customers to 
their partner branch9, thus leaving 43 terminal wholesalers who were successfully interviewed. (Table 4.1) 
 
All 43 terminal wholesalers who were successfully interviewed were asked about their top two supply 
sources for antimalarials.  From a total of 69 wholesaler mentions, 26 referred to foreign manufacturers 
(which are beyond the scope of this study), and the remaining 43 wholesaler mentions referred to 11 unique 
wholesale businesses, called intermediate-1 wholesalers as they supplied terminal wholesalers, all of whom 
had already been identified at the terminal level (as they also supplied retailers included in the Outlet Survey 
sample directly).  As these 11 intermediate-1 wholesalers had already been interviewed at the terminal level, 
an interview was not re-administered; however, a list of intermediate-1 wholesaler suppliers was generated 
from the responses in the 11 interviews conducted at the terminal level, which identified 4 intermediate-2 
wholesalers as they supplied intermediate-1 wholesalers, all of whom had already been identified and 
interviewed at the terminal level.  Repeating this process once again indentified 1 intermediate-3 wholesaler 
who reported an antimalarial manufacturer as their only supply source.  To this effect, the top of the chain 
was deemed to have been reached with a total of 47 wholesalers that stocked antimalarials identified and 43 
interviews completed. 
                                                          
8
 Outlet Survey data collection took place between April and July 2009 and an average exchange rate of 1 US$ to 5342.47 Zambian 
Kwacha was used for the calculation of retail absolute mark-ups.  Supply Chain Survey data collection took place between 28 
February and 6 May 2009 and an average exchange rate of 1 US$ to 5693.71 Zambian Kwacha was used for the calculation of 
wholesale absolute mark-ups.  Historical exchange rates averaged over the specified periods were obtained from 
http://www.oanda.com/currency/historical-rates.  
9
 This respondent did not rescind consent, so where responses were recorded, these contribute to calculated indicators 
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Table 4.1: Overview of the wholesalers sampled and interviewed 
Levels of  
operation 
Initial 
Sample 
Size 
Number 
identified at 
previous 
level(s) 
Number of 
refusals 
Number of 
duplicates
1
 
Number 
not 
eligible
2
 
Number not 
interviewed 
for other 
reasons
3
 
Number 
not found 
Number of 
interviews 
conducted
4
 
Total - - 1 0 9 2 1 44 
Terminal 57 - 1 0 9 2 1 44 
Intermediate-1 11 11 0 0 0 0 0 0 
Intermediate-2 4 4 0 0 0 0 0 0 
Intermediate-3
5
 1 1 0 0 0 0 0 0 
1: Wholesalers included in the initial sample and found to be duplicates during data collection.  2: Outlets not stocking antimalarials or 
RDTs at the time of the interview or in the preceding 3 months.  3: At terminal level, 2 were not interviewed as a suitable respondent was 
not available following 3 visits.  4: At terminal level, 1 respondent stopped the interview to indicate that they refer all wholesale customers 
to their partner branch, resulting in 1 partial interview and 43 completed interviews.  5: This is the top of the chain, defined as the level at 
which wholesalers who were reported to supply intermediate-2 wholesalers mentioned only manufacturers as top supply sources for 
antimalarials. In the ACTwatch protocol, this level was referred to as the primary level where wholesalers who receive supplies directly from 
manufacturers operated. Following the protocol classification, there would be 13 primary suppliers, all of which received supplies from 
foreign manufacturers. 
 
 
 
4.2. Structure of the private commercial sector distribution chain for antimalarial 
drugs 
The structure of the private commercial sector distribution chain for antimalarials in Zambia is depicted in 
Figures 4.2.1 and 4.2.2.  In Figure 4.2.1, each red dot represents a mutually exclusive group of wholesalers 
which are defined by the specific supply chain levels that each wholesaler group serves (these interactions 
are shown by the array of arrows emanating from each dot).  The relative size of each group is shown in the 
attached percentage.  Figure 4.2.2 depicts how wholesalers have been grouped into the overlapping 
analytical categories used throughout this report, while Table 4.2 shows how these analytical categories 
have been derived from the mutually exclusive categories depicted in Figure 4.2.1. 
 
 The observed maximum number of steps from manufacturers’ factory gate to retail outlet is 5: 
manufacturer  intermediate-3 wholesaler  intermediate-2 wholesaler  intermediate-1 wholesaler 
 terminal wholesaler  retailer. 
 All wholesalers surveyed, regardless of supply chain level, were observed to sell directly to retailers and 
nearly 20% of these also supplied other wholesalers (i.e. horizontal trading) 
 There were no observed instances of private sector antimalarial wholesalers or retailers reporting a 
public sector source as one of their two top suppliers of antimalarials; however, 8 (out of 286) eligible 
public facilities at outlet level reported a private sector source as one of their two top antimalarial 
suppliers. 
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Figure 4.2.1: Representation of the antimalarial 
distribution chain showing interactions between 
supply chain levels by mutually exclusive 
wholesaler category 
 
WS: wholesaler;  INT: intermediate 
Figure 4.2.2: Representation of the 
antimalarial distribution chain showing the 
overlap between wholesaler categories used 
for analysis 
 
 
 
Table 4.2: Defining analytical categories from mutually exclusive wholesaler categories 
WHOLESALER 
CATEGORIES 
Total 
number 
identified 
MUTUALLY EXCLUSIVE CATEGORIES ANALYTICAL CATEGORIES 
Supplies 
retailer 
Supplies 
intermediate 1, 
terminal & 
retailer 
Supplies 
terminal & 
retailer 
Supplies 
intermediate 2, 
intermediate 1, 
terminal & 
retailer 
Supply 
Retailers 
Supply 
Wholesalers 
% of wholesalers 100% 80.7% 5.3% 12.3% 1.8% 100.0% 19.3% 
(N) (57) (46) (3) (7) (1) (57) (11) 
 
 
Note: this table presents the number of wholesalers identified and not only those interviewed 
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4.3. Wholesaler characteristics and business practices 
4.3.1. Years in operation, outlet size and range of products sold 
 Wholesale businesses ranged in size, with wholesalers that supply retailers being smaller (median of 8 
workers) than those supplying other wholesalers (median of 20 workers). Both groups had been in 
operation for a median of 9 years. 
 More than 70% of wholesalers supplying the retail level sold other products alongside pharmaceutical 
products.  The most common consumer goods stocked were toiletries (59% of all wholesalers) and 
household goods (35% of all wholesalers). 
 
 
Table 4.3.1: Years in operation, outlet size and range of products sold 
 WHOLESALER CATEGORIES 
CHARACTERISTICS 
SUPPLY 
WHOLESALERS 
SUPPLY RETAILERS 
(ALL WHOLESALERS) 
Years in operation Median 8.5 9 
 IQR 7-10 7-16 
  (N) (10) (42) 
Number of people working at outlet Median 20 8 
 IQR 10-40 5-15 
 (N) (10) (43) 
Sells other products in addition to 
pharmaceuticals1 
% 40.0 70.5 
(N) (10) (44) 
IQR: Inter-quartile Range; 1: other products included toiletries, mobile air time, cigarettes, prepared food, 
groceries and/or household goods 
 
 
4.3.2. Wholesalers’ customers, delivery activities and credit facilities 
 Private clinics, surgeries or hospitals were the most frequently mentioned customers by wholesalers 
(83.7%), pharmacies and drug stores (77.2%), and public and mission health facilities (mentioned by 70-
75% of wholesalers); nearly 57% of wholesalers reported serving retail customers. 
 Only 15% of wholesalers interviewed reported selling antimalarials to customers in other countries; 13% 
of wholesalers had customers in Zimbabwe, 5% in both DRC and Malawi, and 3% in Mozambique.  
 Nearly half (48.8%) of all wholesalers interviewed reported importing antimalarials, while 41.5% 
identified a manufacturer as one of their two top antimalarial suppliers. 
 Two-thirds (67.4%) of all wholesalers reported delivering antimalarials to their customers. 
 More than 60% of all wholesalers interviewed had offered credit to customers in the past 3 months, 
offering a median of 30 days credit (IQR 30-30).  Wholesalers operating at the higher levels of the supply 
chain (i.e. wholesalers supplying wholesalers) were observed to offer comparatively longer credit terms 
(median of 60 days, IQR 30-60). 
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Table 4.3.2: Wholesalers’ Customers, Delivery Activities and Credit facilities 
 WHOLESALER CATEGORIES 
ANTIMALARIAL CUSTOMER TYPES 
SUPPLY 
WHOLESALERS 
SUPPLY RETAILERS 
(ALL WHOLESALERS) 
Retail Customers (e.g. patients, care-takers) % 20.0 56.8 
 (N) (10) (44) 
Retail Outlets 
Pharmacies or drug stores % 100.0 77.2 
 (N) (10) (44) 
General retailers (grocery stores, kiosks, 
containers, mobile providers, kantembas, etc.)  
% 10.0 22.7 
(N) (10) (44) 
Medical Stores Limited1 % 50.0 21.4 
 (N) (10) (42) 
Public health centres % 100.0 75.0 
 (N) (10) (44) 
Public hospitals % 80.0 70.5 
 (N) (10) (44) 
Private clinics, surgeries or hospitals % 100.0 83.7 
 (N) (10) (43) 
Mission clinics or hospitals % 80.0 72.7 
 (N) (10) (44) 
Wholesale Outlets 
Drug wholesalers % 90.02 50.0 
 (N) (10) (44) 
General wholesalers % 0.0 2.3 
 (N) (10) (44) 
Customers in Other Countries % 10.0 15.0 
 (N) (10) (40) 
BUSINESS PRACTICES 
SUPPLY 
WHOLESALERS 
SUPPLY RETAILERS 
(ALL WHOLESALERS) 
Import antimalarial drugs % 90.0 48.8 
(N) (10) (43) 
Buy directly from antimalarial manufacturers (as 
one of two top antimalarial suppliers) 
% 90.0 41.5 
(N) (10) (41) 
Deliver antimalarials to customers % 90.0 67.4 
(N) (10) (43) 
Provided credit to customers in the past 3 months % 80.0 62.8 
(N) (10) (43) 
Most common terms of credit offered in the past 3 
months (number of days) 
Median 60 30 
IQR 30-60 30-30 
(N) (7) (25) 
1: Zambia’s Medical Stores Limited (MSL) is a government-owned company mandated to stock and distribute all 
pharmaceuticals, medical supplies and other health commodities procured by or for the Zambian government; 2: One of 
the ten wholesalers in this category reported that they did not supply drug wholesalers; however, during the supply 
chain survey, a wholesale respondent identified this particular wholesaler as one of their top two supply sources for 
antimalarials. To remain consistent across indicators, we have chosen to report this indicator as 90.0% rather than 
100.0% based on the information reported by respondents. 
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4.4. Licensing & inspection 
 Three-quarters (75.6%) of all wholesalers reported having a wholesale pharmacy license, and nearly a 
third (28.2%) reported having a retail pharmacy licence. 
 Any up-to-date license (i.e. either a retail or wholesale pharmacy license) from the Pharmaceutical 
Regulatory Authority was observed in 70.0% of all wholesalers, and an up-to-date wholesale pharmacy 
license was observed in 55.0% of wholesalers.  
 While 100% of wholesalers who operated at higher levels of the supply chain (i.e. wholesalers supplying 
wholesalers) reported having a wholesale license, an up-to-date wholesale license was only observed in 
60% of these wholesalers. 
 The proportion of wholesalers who reported having an import license is consistently greater or equal to 
the number of wholesalers who reported that they imported antimalarials: 70% of all wholesalers 
interviewed reported having an import license while 49% reported importing antimalarials; 90% of 
wholesalers that supply other wholesalers reported having an import license and the same proportion 
reported importing antimalarials. 
 However, the percentage of wholesalers that reported selling antimalarials directly to retail customers 
(56.8%) was higher than the percentage of wholesalers that reported having the required license to do 
so (28.2%). 
 Nearly all (97.5%) wholesalers interviewed reported that they had been visited by a pharmaceutical 
inspector in the past year. 
 
Table 4.4: Licensing & Inspection 
 WHOLESALER CATEGORIES 
REGISTRATION STATUS 
SUPPLY 
WHOLESALERS 
SUPPLY RETAILERS 
(ALL WHOLESALERS) 
Reported having a license allowing wholesale of 
pharmaceuticals 
% 100.0 75.6 
(N) (10) (41) 
Reported having a license allowing retail of 
pharmaceuticals 
% 0.0 28.2 
(N) (10) (39) 
Reported having an import license % 90.0 70.0 
 (N) (10) (40) 
Reported having a exporter license %  0.0 0.0 
 (N) (10) (39) 
Reported having a manufacturer license %  11.1 5.3 
 (N) (9) (38) 
Any up-to-date license from the Pharmaceutical 
Regulatory Authority was observed1 
%  60.0 70.0 
(N) (10) (40) 
An up-to-date wholesale license from the 
Pharmaceutical Regulatory Authority was observed1 
%  60.0 55.0 
(N) (10) (40) 
An up-to-date general business or trading license 
was observed 
%  80.0 86.0 
(N) (10) (43) 
Reported they had been visited by a pharmaceutical 
inspector in the past year 
% 100.0 97.5 
(N) (10) (40) 
1: This license may be either a retail or wholesale license 
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4.5. Knowledge, qualifications and training 
 More than three-quarters of wholesalers (76.7%) were able to correctly identify artemether-
lumefantrine as the government recommended first-line treatment for uncomplicated malaria. 
 However, the percent of wholesalers identifying this drug, or any other ACT, as the most effective 
medication for treating uncomplicated malaria was somewhat lower (61.9% for children and 69.0% for 
adults). 
 Almost all wholesalers reported employing staff with health qualifications.  The most commonly 
reported health qualifications included pharmacists (90.5% of the 42 wholesalers who answered the 
question ‘do you employ a staff with health qualifications?’ reported at least one staff with pharmacist 
qualifications), followed by pharmacy technologists (78.6%), and dispenser (29.3%). 
 The percentage of wholesalers who indicated that staff had participated in in-service training related to 
malaria treatment in the past 2 years was very low, with only 5% of wholesalers that supply retailers 
having staff who participated in such training, while no wholesalers that supply wholesalers had staff 
who participated in such training 
 
Table 4.5: Wholesalers’ knowledge, qualifications and training 
 WHOLESALER CATEGORIES 
HEALTH QUALIFICATIONS, TRAINING AND KNOWLEDGE 
SUPPLY 
WHOLESALERS 
SUPPLY RETAILERS 
(ALL WHOLESALERS) 
Employ a member of staff with health 
qualifications1 
% 100.0 97.6 
(N) (10) (42) 
Employ staff who participated in in-service 
training related to malaria treatment 
% 0.0 4.9 
(N) (10) (41) 
Identify any ACT as the most effective medication 
for treating uncomplicated Pf malaria in adults 
% 70.0 69.0 
(N) (10) (42) 
Identify any ACT as the most effective medication 
for treating uncomplicated Pf malaria in children 
% 60.0 61.9 
(N) (10) (42) 
Correctly identify the government recommended 
first line treatment for uncomplicated Pf malaria 
% 90.0 76.7 
(N) (10) (43) 
1: Health qualifications included pharmacist, pharmacy technologist, dispenser, medical doctor, nurse, 
midwife, clinical officer, dental surgeon, laboratory technician, veterinary technician, microbiologist 
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4.6. Storage of antimalarial drugs 
 Almost all wholesalers (97.2%) were observed to store antimalarials in a dry area and out of direct 
sunlight; although a smaller percentage (91.7%) was observed to keep them off the floor. 
 Only 86.1% of all wholesalers met all specified conditions for good storage of antimalarials (in a dry area, 
out of direct sunlight and off the floor); however, among the wholesalers supplying other wholesalers, 
100% complied with all conditions. 
 
Table 4.6: Wholesalers’ storage practices 
 WHOLESALER CATEGORIES 
STORAGE 
SUPPLY 
WHOLESALERS 
SUPPLY RETAILERS 
(ALL WHOLESALERS) 
Store antimalarials in a dry area % 100.0 97.2 
(N) (7) (36) 
Store antimalarials out of direct sunlight % 100.0 97.2 
(N) (7) (36) 
Store antimalarials off the floor % 100.0 91.7 
(N) (7) (36) 
Store antimalarials in a dry area, out of direct 
sunlight & off the floor 
% 100.0 86.1 
(N) (7) (36) 
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4.7. Availability of antimalarials & RDTs 
 Nearly all wholesalers surveyed (93%) had at least one antimalarial in stock at the time of interview  
 More than two-thirds of all wholesalers surveyed (72.1%) had an ACT in stock at the time of interview, 
and 68.1% of all wholesalers reported having had at least one ACT in stock throughout the three month 
period prior to interview 
 A higher proportion of wholesalers had non-WHO prequalified ACTs in stock (62.8%) compared to WHO 
prequalified ACTs (44.2%) 
 One third of all wholesalers were observed to stock oral AMTs (32.6%) and non-oral AMTs (34.9%); while 
two-thirds of wholesalers (76.7%) were observed to stock nATs 
 Artemether-lumefantrine, the first-line treatment for uncomplicated malaria, was stocked by 67.4% of 
all wholesalers 
 Artemether-lumefantrine was also the most frequently observed antimalarial, accounting for 24.0% of 
all antimalarial products stocked by wholesalers and 66.3% of all ACTs stocked, followed by 
sulphadoxine-pyrimethamine (19.9% of all antimalarial products stocked), and artemether monotherapy 
(15.9% of all antimalarial products stocked, a third of which were oral dosage forms) 
 The second most frequently observed ACT stocked by wholesalers after artemether-lumefantrine was 
artesunate-sulphamethoxypyrazine-pyrimethamine, accounting for 8.9% of all antimalarial products 
stocked by wholesalers and 24.5% of all ACTs stocked. 
 RDTs were stocked by less than a quarter (23.3%) of all wholesalers at the time of interview 
 
Table 4.7: Antimalarial & RDT availability 
 WHOLESALER CATEGORIES 
AVAILABILITY 
SUPPLY 
WHOLESALERS 
SUPPLY RETAILERS 
(ALL WHOLESALERS) 
Had antimalarials in stock  % 90.0 93.0 
(N) (10) (43) 
Had ACT in stock  % 90.0 72.1 
(N) (10) (43) 
Always had at least one ACT in stock over the past 
3 months 
% 70.0 62.8 
(N) (10) (43) 
Had WHO prequalified ACT in stock % 50.0 44.2 
(N) (10) (43) 
Had non-WHO prequalified ACT in stock % 70.0 62.8 
(N) (10) (43) 
Had oral AMT in stock  % 20.0 32.6 
(N) (10) (43) 
Had non-oral AMT in stock  % 40.0 34.9 
(N) (10) (43) 
Had nAT in stock % 50.0 76.7 
(N) (10) (43) 
Had RDT in stock  % 30.0 23.3 
(N) (10) (43) 
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4.8. Sales volumes of antimalarials and RDTs 
Sales volume data are presented first for all wholesalers (Table 4.8.1) and secondly for only those 
wholesalers stocking the corresponding product category (Table 4.8.2). 
 Among wholesalers who sold antimalarials the week before the survey (n=40), only a quarter (25.0%) of 
all wholesalers reported the recommended first line treatment for uncomplicated malaria, artemether-
lumefantrine (AL), to be their top selling antimalarial, while half (52.5%) of all wholesalers reported 
sulphadoxine-pyrimethamine (SP) to be their top selling antimalarial.10 
 However, AL was reported to be the top selling antimalarial drug by 44.4% of wholesalers supplying 
wholesalers, while SP was the top selling antimalarial among 33.3% of these wholesalers.  Another ACT, 
artesunate-sulphamethoxypyrazine-pyrimethamine, was the third most commonly reported top selling 
antimalarial within this group of wholesalers (22.2%). 
 Among all wholesalers, the median number of adult equivalent treatment doses (AETDs) sold the week 
preceding the survey was 35.7 (IQR 0.8-176.8) for ACTs and 0 (IQR 0-9.2) for AMT.  For nATs, the median 
number of AETDs sold was 320.9 (IQR 13.3-1260.4).  25% of all wholesalers reported not having sold an 
ACT during the week preceding the survey, while the figure was 60% for AMTs.  In contrast, 75% of all 
wholesalers reported having sold nATs during the week preceding the survey.    
 As expected, the median sales volumes for ACTs among wholesalers that supply other wholesalers 
(450.0 AETDs, IQR 90.0-1000.0) was higher than that observed among those that supply retailers; but the 
reverse was observed with respect to nATs, where wholesalers that supply wholesalers were observed 
to have sold a median of 0 AETDs (IQR 0-8136.7) in the week prior to the survey. 
 When ACTs were stocked and sold by wholesalers, the median sales volumes of WHO prequalified ACTs 
(30.0, IQR 2.0-80.0) were similar to non-WHO prequalified ACTs (35.6, IQR 7.0-239.8); however among 
wholesalers supplying other wholesalers, the median sales volumes of WHO prequalified ACTs (500.0, 
IQR 50.0-3721.0) was substantially larger than for non-WHO prequalified ACTs (242.3, IQR 37.5-1000.0). 
 Although ACT and nATs were stocked and sold by a similar number of wholesalers (n=31 vs. n=33, 
respectively), the median sales volumes of nATs (620.0, IQR 61.7-1750.0) was much larger than for ACTs 
(65.0, IQR 17.0-300.0). 
 Although RDTs were not commonly stocked by wholesalers, among those who did stock RDTs, the 
volume of tests sold varied widely both within and across supply chain levels.  Among all wholesalers 
who stocked RDTs, the median number of tests sold during the week preceding the survey was 0 (IQR 0-
250); however, among wholesalers supplying wholesalers, the median number of tests sold was 250 (IQR 
0-400). 
 
  
                                                          
10
The analysis of the top selling antimalarials used sales volumes data collected for each antimalarial in stock at the time of the 
survey:  in each outlet and for each antimalarial stocked, wholesalers were asked to recall the quantity they had sold during the week 
preceding the survey 
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Table 4.8.1: Median number of AETDs & RDTs sold during the week preceding the survey (all wholesalers) 
ANTIMALARIAL TYPE
1
 
Formulation 
WHOLESALER CATEGORIES 
SUPPLY 
WHOLESALERS 
SUPPLY RETAILERS 
(ALL WHOLESALERS) 
N=9 N=40
2 
All ACT All Median 450.0 35.7 
IQR 90.0-1000.0 0.8-176.8 
Tablet Median 242.3 31.0 
IQR 90.0-500.0 0.0-96.3 
Oral liquid Median 0.0 0.0 
IQR 0.0-0.0 0.0-3.8 
WHO prequalified 
ACT 
All products 
were tablets 
Median 2.0 0.0 
IQR 0.0-500.0 0.0-25.0 
Non-WHO 
prequalified ACT 
All Median 90.0 7.7 
IQR 6.0-400.0 0.0-78.4 
Tablet Median 90.0 6.0 
IQR 6.0-242.3 0.0-43.8 
Oral liquid Median 0.0 0.0 
IQR 0.0-0.0 0.0-3.8 
AMT All Median 7.0 0.0 
IQR 0.0-172.5 0.0-9.2 
Tablet Median 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 
Oral liquid Median 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 
Injectable Median 0.0 0.0 
IQR 0.0-41.3 0.0-3.9 
nAT All Median 0.0 320.9 
IQR 0.0-8136.7 13.3-1260.4 
Tablet Median 0.0 301.6 
IQR 0.0-8110.0 0.0-1200.0 
Oral liquid Median 0.0 0.0 
IQR 0.0-0.0 0.0-3.4 
Injectable Median 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 
RDT
3
 (per unit) Median 0.0 0.0 
IQR 0.0-0.0 0.0-0.0 
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: 
Rapid diagnostic test for malaria; 2
 
For antimalarials: there were a total of 40 wholesalers with antimalarial sales 
volumes (reported or imputed or set as null if did not stock). Note on imputation process for antimalarial sales 
volumes: during the study, 57 wholesalers were identified, of which 14 were excluded from the volumes analysis (9 
did not stock antimalarials at the time of interview, 1 refused to participate, 2 were not interviewed because a 
suitable respondent was not available following 3 visits, 1 could not be located, and 1 stopped the interview to 
indicate that they refer all wholesale customers to their partner branch). Of the remaining 43 wholesalers 
successfully interviewed, 1 was excluded from the volume analysis as it did not stock antimalarial at the time of 
interview, but did at some point in the 3 months prior to interview (Table 1). The volumes for 2 wholesalers were set 
as missing for all antimalarial categories as they reported stocking antimalarials but no audit sheet information was 
recorded, leaving the remaining 40 wholesalers included in the volume analysis.  Overall, there were a total of 271 
antimalarials audited, of which 36 (13.3%) had missing sales volumes that were imputed using the mi impute pmm 
command.  3
 
For RDTs, 40 of the 57 wholesalers identified reported that they did not stock RDTs, and 14 reported 
stocking RDT from whom inventory data were collected from 10 wholesalers for 10 different products (responses 
were not recorded for 3 wholesalers).  Of these, 1 did not provide sales volume information; however imputation 
was not performed as there were too few observations to reliably perform linear regression.  Sales volumes were set 
as missing for the 4 wholesalers who reported stocking RDTs but from whom inventory data were not collected. 
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Table 4.8.2: Median number of AETDs & RDTs sold during the week preceding the survey (among 
wholesalers stocking corresponding antimalarial drug category/RDT at the time of the survey) 
ANTIMALARIAL TYPE
1
 
Formulation 
WHOLESALER CATEGORIES
2
 
SUPPLY 
WHOLESALERS 
SUPPLY RETAILERS 
(ALL WHOLESALERS) 
All ACT All Median 450.0 65.0 
IQR 90.0-1000.0 17.0-300.0 
(n) (9) (31) 
Tablet Median 242.3 54.0 
IQR 90.0-500.0 17.0-242.3 
(n) (9) (31) 
Oral liquid Median 487.5 3.8 
IQR 300.0-675.0 1.9-16.9 
(n) (2) (19) 
WHO 
prequalified 
ACT 
All products were 
tablets 
Median 500.0 30.0 
IQR 50.0-3721.0 2.0-80.0 
(n) (5) (19) 
Non-WHO 
prequalified 
ACT 
All Median 242.3 35.6 
IQR 37.5-1000.0 7.0-239.8 
(n) (7) (27) 
Tablet Median 100.0 31.2 
IQR 37.5-325.0 6.0-100.0 
(n) (7) (26) 
Oral liquid Median 487.5 3.8 
IQR 300.0-675.0 1.9-16.9 
(n) (2) (19) 
AMT All Median 172.5 7.9 
IQR 18.8-250.0 0.0-34.4 
(n) (5) (22) 
Tablet Median - 6.3 
IQR - 0.6-26.6 
(n) - (7) 
Oral liquid Median 75.0 1.9 
IQR 18.8-131.3 0.0-5.9 
(n) (2) (13) 
Injectable Median 145.6 7.0 
IQR 24.1-316.9 1.9-87.5 
(n) (4) (15) 
nAT All Median 8136.7 620.0 
IQR 900.5-10075.0 61.7-1750.0 
(n) (5) (33) 
Tablet Median 8110.0 550.0 
IQR 650.0-10000.0 59.8-1500.0 
(n) (5) (32) 
Oral liquid Median 50.8 6.5 
IQR 26.7-75.0 2.3-24.2 
(n) (2) (16) 
Injectable Median 127.6 363.3 
IQR 4.8-250.5 127.6-3095.2 
(n) (2) (4) 
RDT (units) Median 250 0 
IQR 0-400 0-250 
(n) (3) (9) 
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; 
RDT: Rapid diagnostic test for malaria.  2 (n) is the number of wholesalers at a given level who stocked 
antimalarials for corresponding drug category or who stocked RDT. 
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4.9. Purchase price of antimalarials and RDTs 
Purchase price is the price paid by businesses (i.e. wholesalers or outlets) for their most recent purchase of 
an antimalarial product from their suppliers, and is reported in terms of the median price (in US dollars) per 
AETD.  Because of the varied nature of wholesaler transactions (e.g. wholesalers may vary their price; 
antimalarials may pass through a number of wholesalers before reaching an outlet), wholesale purchase 
prices are indicative of the purchase prices paid by wholesalers in general, rather than at specific levels of 
the supply chain.  Retail purchase prices, however, reflect the antimalarial purchase prices paid by specific 
outlet types to their suppliers. 
 
 Median wholesale purchase price per AETD ranged from US$ 0.27 (IQR 0.14-2.42) for nATs, and US$ 
5.09 (IQR 3.51-7.03) for ACTs, to US$ 8.90 (IQR 4.36-16.49) for AMTs. 
 Across different retail outlet types, the median retail purchase price per AETD for ACTs ranged from US$ 
0.94 (IQR 0.94-0.94, 1 observation in grocery stores) to US$ 5.62 (IQR 4.44-7.49) in pharmacies; for 
AMTs from US$ 4.49 (IQR 3.46-5.54) in drug stores to US$ 10.11 (IQR 7.86-19.09) in private health 
facilities; and for nATs from US$ 0.16 (IQR 0.07-0.27) in grocery stores to US$ 1.12 (IQR 0.19-6.74) in 
pharmacies.  Registered pharmacies and private health facilities tended to have paid higher purchase 
prices for antimalarials compared to drug stores and grocery stores, however, a higher proportion of 
the products purchased by registered pharmacies and private health facilities were non-tablets (e.g. 
suspensions or injectables), paediatric formulations, and ‘premium priced’ products (i.e. products, such 
as halofantrine, strategically priced at, or near, the high end of the price range to attract status-
conscious consumers).  Public health facilities usually did not pay for their antimalarial purchases. 
 For AL, the first-line treatment for uncomplicated Pf malaria, the median purchase price per AETD was 
US$ 5.62 (IQR 4.42-7.99) at pharmacies, US$ 5.24 (IQR 4.12-8.98) at private health facilities, US$ 1.50 
(IQR 1.07-2.50) at drug stores, and US$ 0.94 (IQR 0.94-0.94) at grocery stores; at the wholesale level 
supplying retailers, median purchase price was US$ 5.29 (IQR 3.51-8.66) and US$ 4.90 (IQR 3.51-7.96) at 
the level supplying wholesalers. 
 For SP, the antimalarial with the highest number of AETDs distributed, the median purchase price per 
AETD was US$ 0.19 (IQR 0.17-0.28) at pharmacies, US$ 0.12 (IQR 0.09-0.22) at private health facilities, 
US$ 0.19 (IQR 0.12-0.28) at drug stores, and US$ 0.14 (IQR 0.05-0.16) at grocery stores; at the wholesale 
level, median purchase price was US$ 0.14 (IQR 0.09-0.20). 
 As expected, median purchase prices tended to be higher for oral liquids than tablets for ACTs, AMTs 
and nATs; and higher still on injectables for both AMTs and nATs. 
 Wholesalers supplying retailers reported purchasing 1 RDT unit at US$ 5.19 (IQR 2.85-7.56) and 
wholesalers supplying wholesalers at US$ 3.06 (IQR 3.06-3.06). 
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    Table 4.9.1 Purchase price per AETD/RDT (US$), wholesale level 
ANTIMALARIAL TYPE
1
 
Formulation  
WHOLESALER CATEGORIES 
SUPPLY 
WHOLESALERS 
SUPPLY RETAILERS 
(ALL WHOLESALERS) 
N=9 N=40 
All ACT All Median 4.14 5.09 
IQR 3.51-5.44 3.51-7.03 
(n) (7) (58) 
Tablet Median 3.92 4.35 
IQR 3.51-4.14 3.16-5.27 
(n) (5) (41) 
Oral liquid Median 6.43 9.13 
IQR 4.90-7.96 7.03-12.18 
(n) (2) (17) 
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 3.51 4.92 
IQR 3.51-3.51 4.04-5.62 
(n) (1) (13) 
Non WHO 
prequalified 
ACT 
All Median 4.52 5.27 
IQR 3.92-5.44 3.34-8.66 
(n) (6) (45) 
Tablet Median 4.03 3.80 
IQR 3.48-4.79 3.16-5.09 
(n) (4) (28) 
Oral liquid Median 6.43 9.13 
IQR 4.90-7.96 7.03-12.18 
(n) (2) (17) 
AMT All Median 16.22 8.90 
IQR 9.93-22.51 4.36-16.49 
(n) (2) (32) 
Tablet Median - 4.22 
IQR - 3.65-5.20 
(n) - (9) 
Oral liquid Median - 6.43 
IQR - 4.65-10.40 
(n) - (8) 
Injectable Median 16.22 16.11 
IQR 9.93-22.51 10.75-46.37 
(n) (2) (15) 
nAT All Median 4.33 0.27 
IQR 4.33-4.33 0.14-2.42 
(n) (1) (51) 
Tablet Median 4.33 0.20 
IQR 4.33-4.33 0.13-0.74 
(n) (1) (41) 
Oral liquid Median - 2.63 
IQR - 1.90-7.38 
(n) - (9) 
Injectable Median - 3.69 
IQR - 3.69-3.69 
(n) - (1) 
RDT (per unit) Median 3.06 5.19 
IQR (3.06-3.06) (2.85-7.56) 
(n) (1) (4) 
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin 
therapy; RDT: Rapid diagnostic test for malaria.  
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Table 4.9.2 Purchase price per AETD (US$), retail level 
ANTIMALARIAL TYPE
1
 
Formulation  
RETAILER CATEGORIES
2
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
DRUG 
STORES 
GROCERY 
STORES 
PUBLIC 
HEALTH 
FACILITIES 
N=39 N=27 N=92 N=33 N=160 
All ACT All Median 5.62 5.24 1.50 0.94 0.00 
IQR 4.44-7.49 3.93-9.48 1.07-2.50 0.94-0.94 0.00-0.00 
(n) (123) (22) (15) (1) (459) 
Tablet Median 5.52 5.24 1.12 0.94 0.00 
IQR 4.12-6.74 3.93-6.55 1.07-1.87 0.94-0.94 0.00-0.00 
(n) (96) (16) (12) (1) (457) 
Oral liquid Median 8.74 9.48 2.50 - 3.74 
IQR 8.04-11.36 7.99-9.48 2.50-3.69 - 0.00-3.74 
(n) (27) (6) (3) - (2) 
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 5.62 5.24 1.12 0.94 0.00 
IQR 5.62-7.49 2.81-5.99 1.07-1.87 0.94-0.94 0.00-0.00 
(n) (28) (7) (12) (1) (453) 
Non WHO 
prequalified 
ACT 
All Median 5.52 5.99 2.50 - 0.00 
IQR 4.02-8.61 4.68-9.48 2.50-3.69 - 0.00-3.74 
(n) (95) (15) (3) - (6) 
Tablet Median 4.68 5.24 - - 0.00 
IQR 3.46-6.16 3.93-7.30 - - 0.00-0.00 
(n) (68) (9) - - (4) 
Oral liquid Median 8.74 9.48 2.50 - 3.74 
IQR 8.04-11.36 7.99-9.48 2.50-3.69 - 0.00-3.74 
(n) (27) (6) (3) - (2) 
AMT All Median 9.66 10.11 4.49 - 0.00 
IQR 5.39-14.60 7.86-19.09 3.46-5.54 - 0.00-0.00 
(n) (49) (10) (5) - (6) 
Tablet Median 3.74 - 5.54 - 0.00 
IQR 2.70-5.14 - 3.46-5.54 - 0.00-0.00 
(n) (9) - (3) - (4) 
Oral liquid Median 11.53 8.98 4.49 - 0.00 
IQR 6.46-13.98 7.19-8.98 4.49-4.49 - 0.00-0.00 
(n) (18) (2) (1) - (1) 
Injectable Median 11.23 10.11 44.92 - 0.00 
IQR 5.39-15.72 7.86-19.09 44.92-44.92 - 0.00-0.00 
(n) (22) (8) (1) - (1) 
nAT All Median 1.12 0.39 0.23 0.16 0.00 
IQR 0.19-6.74 0.10-2.53 0.14-0.37 0.07-0.27 0.00-0.00 
(n) (113) (54) (154) (33) (348) 
Tablet Median 0.28 0.19 0.22 0.16 0.00 
IQR 0.17-2.83 0.10-0.94 0.13-0.37 0.07-0.27 0.00-0.00 
(n) (78) (39) (141) (33) (261) 
Oral liquid Median 2.13 2.81 2.25 - 0.00 
IQR 1.40-8.25 2.81-6.68 1.68-5.62 - 0.00-9.83 
(n) (29) (6) (13) - (9) 
Injectable Median 11.79 5.90 - - 0.00 
IQR 7.08-11.79 2.95-6.29 - - 0.00-0.00 
(n) (6) (9) - - (78) 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for malaria. 2 As 
these are weighted medians, medians are not the average of the middle two ordered observations for instances where there are an even number of 
observations. Note: 22 of 1783 (1.2%) purchase price observations (9 in pharmacies, 5 in private health facilities, 7 in drug stores, 1 in grocery stores) were 
set to missing due to mark-ups in excess of 1000% which were likely due to errors during data collection. Data collected by the ACTwatch Group during the 
Zambia 2009 Outlet Survey. www.actwatch.info 
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4.10. Price mark-ups on antimalarials and RDTs 
4.10.1.  Percent Mark-Ups on Antimalarials and RDTs11 
In general, the percentage mark-up is calculated as the difference between the selling price and the purchase 
price, divided by the purchase price.  It captures both the costs of doing business and profit to the seller.  Because 
wholesalers vary their prices, minimum, maximum and mid mark-ups were calculated using data on minimum and 
maximum selling price charged for one unit by wholesalers.  The wholesale percent mid mark-up was calculated 
as the difference between the average wholesale selling price (i.e. the mid-point between the maximum and 
minimum wholesale selling price) and wholesale purchase price, divided by wholesale purchase price.  The retail 
percentage mark-up was calculated using the retail selling price and purchase price collected during the ACTwatch 
Outlet Survey. 
Wholesale level 
 Wholesale-level mid percent mark-ups ranged from 18.8%-28.6% across all antimalarial categories. 
 Wholesalers supplying wholesalers did not commonly vary their prices according to volume purchased; of a 
total of 54 audited products, 51 had wholesale price data, and for only 3 (5.9%) did price vary with volume.  
However, in these 3 cases it was not possible to calculate mark-ups because no purchase prices were 
recorded.  The remaining audited products had prices that did not vary hence the mid, low and high mark-ups 
are the same.  Among wholesalers supplying retailers, there were 271 audited products in total, of which 259 
had wholesale price data, and 42 (16.2%) products were audited where price varied with volume. 
 The mid wholesaler mark up was 26.7% (IQR 20.0-39.5) on ACT, 18.8% (IQR 12.5-24.0) on WHO prequalified 
ACTs, 28.6% (IQR 24.0-42.9) on non-WHO prequalified ACTs, 26.1% (IQR 18.0-33.8) on AMT and 24.7% (IQR 
13.0-50.0) on nATs.  Wholesalers supplying retailers reported lower mark ups than wholesalers supplying 
wholesalers on ACTs, which was driven mainly by mark-ups for non-WHO prequalified products.   
 The median wholesaler mid percent mark up on RDTs was 47.5% (IQR 35.3-85.2) among all wholesalers. 
Retail level 
 Retail level percent mark-ups ranged from 42.9%-233.3% across outlet types and all antimalarial categories, 
and were observed to be generally higher than wholesale-level percent mark-ups. 
 Although public health facilities were observed to apply very high percentage mark-ups on some antimalarial 
drug categories, it was relatively rare to encounter drugs for which there was a charge in public health 
facilities. 
 At the private sector retail level, observed median mark-ups varied considerably both across outlet type and 
antimalarial category, ranging from about 30% to 200%; however, retail pharmacies were observed to 
consistently add the lowest mark-ups across different antimalarial types (mark-up of around 40-80%). 
 Across different retail outlet types, the median mark-up on ACT ranged between 42.9% (IQR 37.0-66.7) in 
pharmacies and 200.0% (IQR 84.6-248.8) at drug stores; on AMT between 33.3% (IQR 13.5-54.1) at drug 
stores and 200.9% (IQR 38.9-328.6) at private health facilities; on nAT between 81.8% (IQR 44.4-150.0) at 
pharmacies and 114.3% (IQR 64.5-212.5) at drug stores.  
First-line and most popular treatment 
 For AL, the first-line treatment for uncomplicated malaria, median percent mark-up was 42.9% (IQR 37.0-
66.7) at pharmacies, 71.4% (IQR 47.4-78.6) at private health facilities, and 200.0% (IQR 84.6-248.8) at drug 
stores; at wholesale level, median mid percent mark-up was 19.4% (IQR 10.0-32.4) among wholesalers 
supplying wholesalers, and 24.0% (IQR18.8-34.6) among wholesalers supplying retailers.  
 For SP, the antimalarial with the highest number of AETDs distributed, median percent mark-up was 150.0% 
(IQR 66.7-156.4) at pharmacies, 100.0% (IQR 0-334.8) at private health facilities, 114.3% (IQR 69.5-233.3) at 
drug stores, and 150.0% (IQR 76.5-525.0) at grocery stores; at wholesale levels, median mid percent mark-up 
was 23.9% (IQR 11.1-58.2) among all wholesalers. 
                                                          
11
 Negative % mark-ups were recorded in several cases. There are a number of potential explanations for this:  (1) these may be data 
collection errors (it was noted during training/fieldwork that antimalarials bought in relatively large pack sizes and sold by the tablet 
(i.e. chloroquine) were subject to frequent errors); (2) some businesses may have applied negative mark ups as they sold products at 
lower prices than they bought them to deal with slow moving products or because the purchase price has increased and the business 
was still selling the ‘old’ product at the ‘old’ price.  
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Table 4.10.1.1: Percent price mark-ups on antimalarials and RDTs, wholesale level (%)   
ANTIMALARIAL TYPE
1
 
Formulation  
WHOLESALER CATEGORIES 
SUPPLY WHOLESALERS 
N=9 
SUPPLY RETAILERS  
(ALL WHOLESALERS) 
N=40 
MID LOW HIGH MID LOW HIGH 
All ACT All Median 32.4 32.4 32.4 26.7 24.2 30.0 
IQR 19.4-65.3 19.4-65.3 19.4-65.3 20.0-39.5 17.5-34.6 21.7-42.9 
(n)  (7)   (58)  
Tablet Median 61.4 61.4 61.4 24.2 22.2 29.0 
IQR 27.3-65.3 27.3-65.3 27.3-65.3 18.8-34.6 14.3-34.6 21.7-40.0 
(n)  (5)   (41)  
Oral liquid Median 25.9 25.9 25.9 29.7 27.4 30.2 
IQR 19.4-32.4 19.4-32.4 19.4-32.4 25.0-42.9 23.5-42.9 25.0-42.9 
(n)  (2)   (17)  
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 10.0 10.0 10.0 18.8 14.3 21.7 
IQR 10.0-10.0 10.0-10.0 10.0-10.0 12.5-24.0 12.5-21.7 14.3-30.0 
(n)  (1)   (13)  
Non WHO 
prequalified 
ACT 
All Median 46.9 46.9 46.9 28.6 27.3 30.6 
IQR 27.3-65.3 27.3-65.3 27.3-65.3 24.0-42.9 20.0-42.9 25.0-44.4 
(n)  (6)   (45)  
Tablet Median 63.4 63.4 63.4 28.0 26.2 30.6 
IQR 44.4-66.5 44.4-66.5 44.4-66.5 23.0-43.7 17.6-43.7 24.3-45.4 
(n)  (4)   (28)  
Oral liquid Median 25.9 25.9 25.9 29.7 27.4 30.2 
IQR 19.4-32.4 19.4-32.4 19.4-32.4 25.0-42.9 23.5-42.9 25.0-42.9 
(n)  (2)  (17) (17) (17) 
AMT All Median 7.5 7.5 7.5 26.1 24.0 29.3 
IQR 6.7-8.2 6.7-8.2 6.7-8.2 18.0-33.8 17.7-32.5 18.0-37.6 
(n)  (2)   (32)  
Tablet Median - - - 25.5 21.6 32.1 
IQR - - - 21.6-42.5 19.4-35.0 21.6-50.0 
(n)  -   (9)  
Oral liquid Median - - - 31.0 27.5 34.2 
IQR - - - 20.6-35.0 18.1-32.5 20.8-40.3 
(n)  -   (8)  
Injectable Median 7.5 7.5 7.5 25.0 22.1 25.0 
IQR 6.7-8.2 6.7-8.2 6.7-8.2 11.1-33.0 11.1-30.0 11.1-34.6 
(n)  (2)   (15)  
nAT All Median 82.8 82.8 82.8 24.7 22.7 25.0 
IQR 82.8-82.8 82.8-82.8 82.8-82.8 13.0-50.0 12.5-50.0 13.0-50.0 
(n)  (1)  (53) (53) (53) 
Tablet Median 82.8 82.8 82.8 24.7 22.7 27.7 
IQR 82.8-82.8 82.8-82.8 82.8-82.8 14.6-50.0 12.5-50.0 14.6-50.0 
(n)  (1)   (43)  
Oral liquid Median - - - 25.0 24.9 25.0 
IQR - - - 13.0-50.0 13.0-50.0 13.0-50.0 
(n)  -   (9)  
Injectable Median - - - -84.0 -84.0 -84.0 
IQR - - - -84.0--84.0 -84.0--84.0 -84.0--84.0 
(n)  -   (1)  
RDT (per unit) Median 51.7 51.7 51.7 47.5 47.5 47.5 
IQR 51.7-51.7 51.7-51.7 51.7-51.7 35.3-85.2 34.2-85.2 36.5-85.2 
(n) (1) (1) (1)  (4)  
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for 
malaria. 
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 Table 4.10.1.2: Percent price mark-ups on antimalarials, retail level (%) 
ANTIMALARIAL TYPE
1
 
Formulation  
RETAILER CATEGORIES
2
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
DRUG 
STORES 
GROCERY 
STORES 
PUBLIC 
HEALTH 
FACILITIES 
N=39 N=27 N=92 N=32 N=158 
All ACT All Median 42.9 71.4 200.0 150.0 0.0 
IQR 37.0-66.7 47.4-89.7 84.6-248.8 150.0-150.0 0.0-0.0 
(n) (122) (22) (15) (1) (456) 
Tablet Median 42.9 71.4 233.3 150.0 0.0 
IQR 36.4-66.7 33.3-89.7 84.6-248.8 150.0-150.0 0.0-0.0 
(n) (95) (16) (12) (1) (454) 
Oral liquid Median 42.9 71.4 100.0 - 33.3 
IQR 42.1-59.1 47.4-94.4 1.4-200.0 - 0.0-33.3 
(n) (27) (6) (3) - (2) 
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 50.0 71.4 233.3 150.0 0.0 
IQR 30.0-66.7 50.0-71.9 84.6-248.8 150.0-150.0 0.0-0.0 
(n) (28) (7) (12) (1) (450) 
Non WHO 
prequalified 
ACT 
All Median 42.9 78.6 100.0 - 0.0 
IQR 40.0-59.1 47.4-89.7 1.4-200.0 - 0.0-33.3 
(n) (94) (15) (3) - (6) 
Tablet Median 42.9 78.6 - - 0.0 
IQR 37.0-66.7 23.1-89.7 - - 0.0-0.0 
(n) (67) (9) - - (4) 
Oral liquid Median 42.9 71.4 100.0 - 33.3 
IQR 42.1-59.1 47.4-94.4 1.4-200.0 - 0.0-33.3 
(n) (27) (6) (3) - (2) 
AMT All Median 44.4 200.9 33.3 - 0.0 
IQR 38.5-109.3 38.9-328.6 13.5-54.1 - 0.0-0.0 
(n) (49) (10) (5) - (5) 
Tablet Median 36.4 - 54.1 - 0.0 
IQR 32.0-42.9 - 13.5-54.1 - 0.0-0.0 
(n) (9) - (3) - (3) 
Oral liquid Median 42.9 0.0 33.3 - 0.0 
IQR 40.6-83.7 0.0-66.7 33.3-33.3 - 0.0-0.0 
(n) (18) (2) (1) - (1) 
Injectable Median 66.7 233.3 60.0 - 0.0 
IQR 42.9-295.8 53.8-328.6 60.0-60.0 - 0.0-0.0 
(n) (22) (8) (1) - (1) 
nAT All Median 81.8 100.0 114.3 100.0 0.0 
IQR 44.4-150.0 25.0-396.0 64.5-212.5 51.5-257.1 0.0-0.0 
(n) (113) (54) (154) (32) (346) 
Tablet Median 87.5 100.0 114.3 100.0 0.0 
IQR 48.1-150.0 25.0-328.6 69.5-228.9 51.5-257.1 0.0-0.0 
(n) (78) (39) (141) (32) (259) 
Oral liquid Median 66.7 40.0 50.0 - 0.0 
IQR 42.9-88.9 17.6-100.0 50.0-75.0 - 0.0-33.3 
(n) (29) (6) (13) - (9) 
Injectable Median 66.7 400.0 - - 0.0 
IQR 38.9-66.7 100.0-500.0 - - 0.0-0.0 
(n) (6) (9) - - (78) 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for malaria. 2 As 
these are weighted medians, medians are not the average of the middle two ordered observations for instances where there are an even number of 
observations. Note: 22 of 1783 (1.2%) mark-ups observations (9 in pharmacies, 5 in private health facilities, 7 in drug stores, 1 in grocery stores) were set 
to missing due to mark-ups in excess of 1000% which were likely due to errors during data collection. Data collected by the ACTwatch Group during the 
Zambia 2009 Outlet Survey. www.actwatch.info 
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4.10.2. Absolute mark-ups on antimalarials and RDTs (US$) 
In general, the absolute mark-up is calculated as the difference between the selling price and the purchase 
price per AETD and is reported in US dollars.  It captures both the costs of doing business and profit to the 
seller. Because wholesalers vary their prices, minimum, maximum and mid mark-ups were calculated using 
data on minimum and maximum selling price charged per AETD by wholesalers.  The wholesale absolute mid 
mark-up was calculated as the difference between the average wholesale selling price (i.e. the mid-point 
between the maximum and minimum wholesale selling price) and wholesale purchase price.  The retail 
absolute mark-up was calculated using the retail selling price and purchase price collected during the 
ACTwatch Outlet Survey.  Data were collected in local currencies and converted to their US$ equivalent using 
the average interbank rate for the duration of the fieldwork period. 
 
Wholesale level 
 The mid wholesaler mark-up was US$ 1.58 (IQR 0.88-2.58) on ACT, US$ 0.88 (IQR 0.76-1.05) on WHO 
prequalified ACT, US$ 1.64 (IQR 0.94-2.71) on non-WHO prequalified ACT, US$ 2.20 (IQR 0.98-5.48) on 
AMT and US$ 0.14 (IQR 0.02-0.59) on nAT. 
 As noted in section 4.10.1, for wholesalers supplying wholesalers none of the 51 audited products with 
mark-up data exhibited selling price variation, so mid, low and high mark-ups are the same.  Among 
wholesalers supplying retailers, a total of 271 products were audited, of which 259 had wholesale price 
data, and 42 (16.2%) products were audited where price varied with volume. 
 The median wholesaler mid mark up on RDTs was US$ 2.38 (IQR 1.15-6.22).  
 
Retail level 
 Across different retail outlet types, the median mark-up on ACT ranged between US$ 1.40 (IQR 1.40-
1.40) at grocery stores and US$ 4.12 (IQR 2.06-5.99) at private health facilities; on AMT between US$ 
1.50 (IQR 0.75-1.87) at drug stores and US$ 25.16 (IQR 16.25-25.83) at private health facilities; and on 
nAT between US$ 0.17 (IQR 0.12-0.28) at grocery stores and US$ 0.67 (IQR 0.28-2.83) at pharmacies. 
 Registered pharmacies and private health facilities tended to have higher absolute mark-ups for 
antimalarials compared to drug stores and grocery stores, however, a higher proportion of the products 
purchased by registered pharmacies and private health facilities were non-tablets (e.g. suspensions or 
injectables), paediatric formulations, and ‘premium priced’ products (e.g. halofantrine). 
 
First line and most popular treatment 
 For AL, the first-line treatment for uncomplicated Pf malaria, the median absolute mark-up was US$ 2.99 
(IQR 1.87-3.74) at pharmacies, US$ 4.31 (IQR 2.81-5.99) at private health facilities, US$ 2.67 (IQR 1.37-
3.77) at drug stores, and US$ 1.40 (IQR 1.40-1.40) at grocery stores; at the wholesale level supplying 
retailers, median mid absolute mark-up was US$ 1.32 (IQR 0.79-2.58) and US$ 0.95 (IQR 0.35-2.58) at 
the level supplying wholesalers. 
 For SP, the antimalarial with the highest number of AETDs distributed, the median absolute mark-up was 
US$ 0.28 (IQR 0.17-0.39) at pharmacies, US$ 0.28 (IQR 0.00-0.43) at private health facilities, US$ 0.25 
(IQR 0.17-0.30) at drug stores, and US$ 0.17 (IQR 0.12-0.28) at grocery stores; at the wholesale level, 
median mid absolute mark-up was US$ 0.03 (IQR 0.02-0.12). 
 
 36 
 
Table 4.10.2.2: Absolute price mark ups on antimalarials and RDTs, wholesale level (US$) 
ANTIMALARIAL TYPE
1
 
Formulation  
WHOLESALER CATEGORIES 
SUPPLY WHOLESALERS 
N=9 
SUPPLY RETAILERS  
(ALL WHOLESALERS) 
N=40 
MID LOW HIGH MID LOW HIGH 
All ACT All Median 2.41 2.41 2.41 1.58 1.58 1.58 
IQR 0.83-2.71 0.83-2.71 0.83-2.71 0.88-2.58 0.79-2.58 0.88-2.71 
(n)  (7)   (58)  
Tablet Median 2.41 2.41 2.41 1.05 0.88 1.41 
IQR 0.83-2.71 0.83-2.71 0.83-2.71 0.79-1.58 0.63-1.58 0.88-1.58 
(n)  (5)   (41)  
Oral liquid Median 1.76 1.76 1.76 2.81 2.81 3.04 
IQR 0.95-2.58 0.95-2.58 0.95-2.58 1.88-4.68 1.65-4.68 2.11-4.68 
(n)  (2)   (17)  
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 0.35 0.35 0.35 0.88 0.88 0.88 
IQR 0.35-0.35 0.35-0.35 0.35-0.35 0.76-1.05 0.55-0.88 0.88-1.41 
(n)  (1)   (13)  
Non WHO 
prequalified 
ACT 
All Median 2.49 2.49 2.49 1.64 1.64 1.64 
IQR 0.95-2.71 0.95-2.71 0.95-2.71 0.94-2.71 0.88-2.71 0.97-2.81 
(n)  (6)   (45)  
Tablet Median 2.56 2.56 2.56 1.36 1.23 1.49 
IQR 1.62-3.20 1.62-3.20 1.62-3.20 0.79-2.15 0.75-2.15 0.85-2.15 
(n)  (4)   (28)  
Oral liquid Median 1.76 1.76 1.76 2.81 2.81 3.04 
IQR 0.95-2.58 0.95-2.58 0.95-2.58 1.88-4.68 1.65-4.68 2.11-4.68 
(n)  (2)   (17)  
AMT All Median 1.17 1.17 1.17 2.20 1.86 2.53 
IQR 0.82-1.52 0.82-1.52 0.82-1.52 0.98-5.48 0.84-5.48 0.98-5.48 
(n)  (2)   (32)  
Tablet Median - - - 1.12 1.12 1.41 
IQR - - - 0.84-2.01 0.84-1.76 0.84-2.53 
(n)  -   (9)  
Oral liquid Median - - - 1.47 1.31 1.62 
IQR - - - 1.02-4.71 0.97-4.36 1.08-5.06 
(n)  -   (8)  
Injectable Median 1.17 1.17 1.17 4.22 4.22 4.22 
IQR 0.82-1.52 0.82-1.52 0.82-1.52 1.52-14.05 1.52-13.70 1.52-14.05 
(n)  (2)   (15)  
nAT All Median 3.59 3.59 3.59 0.14 0.12 0.14 
IQR 3.59-3.59 3.59-3.59 3.59-3.59 0.02-0.59 0.02-0.59 0.02-0.59 
(n)  (1)   (50)  
Tablet Median 3.59 3.59 3.59 0.05 0.04 0.05 
IQR 3.59-3.59 3.59-3.59 3.59-3.59 0.02-0.33 0.02-0.28 0.02-0.37 
(n)  (1)   (40)  
Oral liquid Median - - - 0.79 0.79 0.79 
IQR - - - 0.32-1.58 0.32-1.58 0.32-1.58 
(n)  -   (9)  
Injectable Median - - - -3.10 -3.10 -3.10 
IQR - - - -3.10--3.10 -3.10--3.10 -3.10--3.10 
(n)  -   (1)  
RDT (per unit) Median 1.58 1.58 1.58 2.38 2.38 2.38 
IQR 1.58-1.58 1.58-1.58 1.58-1.58 1.15-6.22 1.12-6.22 1.18-6.22 
(n)  (1)   (4)  
1
 
ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for 
malaria. 
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 Table 4.10.2.2: Absolute price mark ups on antimalarials, retail level (US$) 
ANTIMALARIAL TYPE
1
 
Formulation  
RETAILER CATEGORIES
2
 
PHARMACIES 
PRIVATE 
HEALTH 
FACILITIES 
DRUG 
STORES 
GROCERY 
STORES 
PUBLIC 
HEALTH 
FACILITIES 
N=39 N=27 N=92 N=33 N=160 
All ACT All Median 2.81 4.12 2.67 1.40 0.00 
IQR 1.87-3.74 2.06-5.99 1.37-3.77 1.40-1.40 0.00-0.00 
(n) (122) (22) (15) (1) (459) 
Tablet Median 2.47 3.93 2.67 1.40 0.00 
IQR 1.72-3.74 1.87-4.31 1.37-3.77 1.40-1.40 0.00-0.00 
(n) (95) (16) (12) (1) (457) 
Oral liquid Median 4.87 6.49 2.50 - 1.25 
IQR 3.74-6.49 4.49-8.49 0.05-4.99 - 0.00-1.25 
(n) (27) (6) (3) - (2) 
WHO 
prequalified 
ACT 
All products 
were tablets 
Median 2.99 4.31 2.67 1.40 0.00 
IQR 1.87-3.74 2.81-4.31 1.37-3.77 1.40-1.40 0.00-0.00 
(n) (28) (7) (12) (1) (453) 
Non WHO 
prequalified 
ACT 
All Median 2.81 4.12 2.50 - 0.00 
IQR 1.87-4.12 2.06-6.49 0.05-4.99 - 0.00-1.25 
(n) (94) (15) (3) - (6) 
Tablet Median 2.25 3.93 - - 0.00 
IQR 1.59-2.99 1.68-4.12 - - 0.00-0.00 
(n) (67) (9) - - (4) 
Oral liquid Median 4.87 6.49 2.50 - 1.25 
IQR 3.74-6.49 4.49-8.49 0.05-4.99 - 0.00-1.25 
(n) (27) (6) (3) - (2) 
AMT All Median 6.74 25.16 1.50 - 0.00 
IQR 2.92-12.28 16.25-25.83 0.75-1.87 - 0.00-0.00 
(n) (49) (10) (5) - (6) 
Tablet Median 1.46 - 1.87 - 0.00 
IQR 1.20-2.20 - 0.75-1.87 - 0.00-0.00 
(n) (9) - (3) - (4) 
Oral liquid Median 5.77 0.00 1.50 - 0.00 
IQR 3.49-11.23 0.00-4.79 1.50-1.50 - 0.00-0.00 
(n) (18) (2) (1) - (1) 
Injectable Median 10.56 25.83 26.95 - 0.00 
IQR 6.74-15.95 23.58-25.83 26.95-26.95 - 0.00-0.00 
(n) (22) (8) (1) - (1) 
nAT All Median 0.67 0.45 0.26 0.17 0.00 
IQR 0.28-2.83 0.19-2.28 0.19-0.33 0.12-0.28 0.00-0.00 
(n) (113) (54) (154) (33) (348) 
Tablet Median 0.32 0.29 0.25 0.17 0.00 
IQR 0.20-1.57 0.09-0.72 0.19-0.31 0.12-0.28 0.00-0.00 
(n) (78) (39) (141) (33) (261) 
Oral liquid Median 1.50 1.18 2.25 - 0.00 
IQR 0.90-3.93 1.12-2.53 1.12-3.65 - 0.00-3.28 
(n) (29) (6) (13) - (9) 
Injectable Median 7.86 19.65 - - 0.00 
IQR 2.75-7.86 4.07-29.48 - - 0.00-0.00 
(n) (6) (9) - - (78) 
1 ACT: artemisinin-based combination therapy; AMT: artemisinin monotherapy; nAT: non artemisinin therapy; RDT: Rapid diagnostic test for malaria. 2 As 
these are weighted medians, medians are not the average of the middle two ordered observations for instances where there are an even number of 
observations. Note: 22 of 1783 (1.2%) mark-ups observations (9 in pharmacies, 5 in private health facilities, 7 in drug stores, 1 in grocery stores) were set 
to missing due to mark-ups in excess of 1000% which were likely due to errors during data collection. Data collected by the ACTwatch Group during the 
Zambia 2009 Outlet Survey. www.actwatch.info 
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5. Discussion 
Supply Chain Structure and Wholesaler Characteristics 
Broad-based pyramidal structure of private sector distribution chain:  As in other low income countries, the 
private commercial sector distribution chain in Zambia had a pyramidal shape with a very broad base (i.e. 
there are many distributors at the lower level of the chain) and narrowed considerably at the top (i.e. there 
are very few operating at the top of the chain).  While all of the wholesalers indentified were observed to 
supply retailers directly (80% of whom were observed to supply retailers only), we also found that nearly a 
fifth of these (19.3%) were supplying other wholesalers and operated across 4 overlapping levels 
(intermediate-3 wholesalers, intermediate-2 wholesalers, intermediate-1 and terminal wholesalers). 
 
Number of steps:  The maximum number of steps from manufacturers’ factory gate to retailers could be as 
high as 5 (manufacturer  intermediate-3 wholesaler  intermediate-2 wholesaler  intermediate-1 
wholesaler  terminal wholesaler  retailer).  However, as all of the wholesalers who operated at the 
higher levels of the supply chain (i.e. wholesalers supplying wholesaler) were already identified at the 
terminal level and because a high proportion of wholesalers identified a manufacturer as one of their top 
antimalarial suppliers (41.5% of all wholesalers; 90% of wholesalers that supply other wholesalers), it is likely 
that most antimalarials passed through 2 steps (manufacturer  terminal wholesaler  retailer), or a 
maximum of 3 (manufacturer  intermediate-1 wholesaler  terminal wholesaler  retailer). 
 
Factors that could explain the distribution chain structure:  The lack of local manufacturing capacity for 
antimalarials in Zambia is an important factor that likely drives many wholesalers to purchase directly from 
foreign manufacturers. [4]  Our survey showed that a large proportion of wholesalers (70%) reported having 
a license to import pharmaceuticals, and this license was observed in around half of all wholesalers.  Data 
from the ACTwatch Outlet Survey data indicates that the vast majority of antimalarials observed in the 
country (95%) were manufactured elsewhere.  However, entering the market as an antimalarial importer in 
Zambia could be particularly difficult as it is more challenging to cultivate relationships with foreign suppliers 
(often leading to sole distributorships [4]) and importing incurs high transaction costs, particularly as Zambia 
is landlocked and consignments must be large to maximise profits.  Despite the government’s recent focus 
on private sector led development, relatively low access to bank credit and high cost of borrowing (collateral 
requests as high as 100-200%), and high communication and transport costs present additional challenges to 
starting and operating a pharmaceutical wholesaling business in Zambia. [3]  The low numbers of 
wholesalers and the relatively high age of businesses (median of 9 years in operation), could reflect these 
difficulties in market entry.  One instance of a vertically integrated business that engaged in the import, 
wholesale and retail of antimalarials was observed, as was horizontal trading among wholesalers, which is 
consistent with the distribution chain structures in other settings. [15] 
 
Transactions between public and private sectors:  There were no observed instances of private sector 
antimalarial wholesalers or retailers reporting a public sector source as one of their two top suppliers of 
antimalarials; however, 8 (out of 286) eligible public facilities at outlet level reported a private sector source 
as one of their two top antimalarial suppliers and many wholesalers (over 70%) reported public facilities as 
their customers for antimalarials.  While there have been efforts to improve the public sector supply chains 
(e.g. the DELIVER programme), it is reasonable to assume that public facilities make ad hoc purchases from 
private wholesalers where there has been a disruption in their regular supply lines [4]. 
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Wholesaler characteristics:  Wholesale businesses were medium-sized with a median of 8 workers; but 
wholesalers operating at higher levels of the chain tended to be larger with a median of 20 workers.  Most 
wholesalers (70.5%) sold other products in addition to pharmaceuticals, but these tended to be related 
products, such as toiletries (59% of all wholesalers) and household goods (35% of all wholesalers), rather 
than products such as mobile air time (9%), cigarettes (2%) or food (2%). 
 
Business practices within the supply chain:  Two-thirds (67.4%) of all wholesalers reported having organised 
delivery of antimalarial purchases to their customers, and nearly all wholesalers supplying other wholesalers 
(90%) reported doing so.  As most wholesalers were observed to be located in either Lusaka (61%) or the 
Copperbelt Province (23%), and considering the relatively high cost of transportation, organising deliveries is 
a likely strategy designed to attract customers located in various parts of the country.  Despite the relatively 
low access to bank credit in Zambia, many wholesalers (60%) reported having offered credit to customers in 
the past 3 months, offering a median of 30 days’ credit.  However, another study reported that credit is likely 
offered to larger customers, while smaller customers were required to pay for their purchases up front. [4] 
 
Licensing and Inspection 
Only three-quarters (31 of 41) of all wholesalers interviewed reported having a licence to wholesale 
medicines from the Pharmaceutical Regulatory Authority, and an up-to-date wholesaler license was only 
observed in 21 of these (67.7%).  However, a further 7 wholesalers (17.5%) where a valid wholesaler license 
was not observed did have an up-to-date license allowing pharmaceutical retailing.  Because of the bottom-
up approach used for this study to identify de facto wholesalers (i.e. businesses that sell to other 
businesses), it was expected that some retail outlets, such as grocery stores that should not be retailing 
antimalarials, would purchase antimalarial stock from retail drug outlets, such as pharmacies or drug stores.  
Despite this, almost all wholesalers interviewed reported having been visited by a pharmaceutical inspector 
in the 12 months prior to interview and 91% also reported employing a pharmacist, which is a regulatory 
requirement of the PRA to wholesale medicines.   
 
Wholesaler knowledge 
Although Zambia was the first country in Sub-Saharan Africa to adopt ACTs as first-line treatment policy in 
2002, only three-quarters of wholesalers interviewed (76.7%) were able to correctly identify AL as the 
government recommended treatment, and a smaller proportion of wholesalers identified AL, or any other 
ACT, as the most effective medication for treating uncomplicated malaria in either children (61.9%) or adults 
(69.0%).  This could affect demand for ACTs at lower levels of the chain.  One study of antimalarial retailers 
in Zambia found that perceived efficacy of SP was an important factor that led 60% of interviewed 
shopkeepers to recommend SP over other antimalarials to their customers. [16]  The authors suggest that 
this perceived efficacy of SP over AL could, at least in part, be the residual effect of training received during 
Zambia’s transition from chloroquine to AL as first-line treatment, where districts without AL were instructed 
to use SP for uncomplicated malaria;.  As the percentage of wholesalers in our study who indicated that staff 
had participated in in-service training related to malaria treatment in the past 2 years was very low (5% of 
wholesalers that supply retailers, and no wholesalers that supply wholesalers), more training of wholesalers 
on updated malaria treatment guidelines could possibly enhance uptake of ACTs in the private sector.   
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Availability 
ACT availability was relatively high:  More than two-thirds of all wholesalers surveyed (72.1%) had an ACT in 
stock at the time of interview, and 68.1% of all wholesalers reported always having at least one ACT in stock 
throughout the three month period prior to interview, although a higher proportion of wholesalers had non-
WHO prequalified ACTs in stock (62.8%) compared to WHO prequalified ACTs (44.2%).  The recommended 
first-line treatment for uncomplicated malaria, AL, was stocked by 67.4% of all wholesalers and was also the 
most frequently observed antimalarial, accounting for 24.0% of all antimalarial products stocked by 
wholesalers and 66.3%.  Another ACT, artesunate-sulphamethoxypyrazine-pyrimethamine, was the third 
most commonly stocked antimalarial by wholesalers, accounting for 8.9% of all antimalarial products 
stocked by wholesalers. 
AMT and nAT availability was also relatively high, while RDT availability was low:  Despite the ban on AMTs 
that has been in place since 2008, half of all wholesalers were observed to have AMTs in stock, and two-
thirds of wholesalers (76.7%) were observed to stock nATs.  On the other hand, only 23.3% of wholesalers 
were observed to have RDTs in stock at the time of interview; however 40% of wholesalers did report having 
stocked an RDT at least once in the 3 month period preceding the interview. 
 
Sales Volumes 
ACTs are being sold by wholesalers, but in smaller quantities than nATs:  For ACTs, the median number of 
AETDs sold the week preceding the survey among all wholesalers (i.e. both those with and without ACTs in 
stock at the time of interview) was 12.3, and 65.0 AETDs among those wholesalers that had ACTs in stock at 
the time of interview.  In contrast, the volume of nATs sold was much larger: the median number of AETDs 
sold was 77.3 among all wholesalers identified, and 620.0 AETDs among those with nATs in stock.  Sales of 
SP, the most commonly reported top selling antimalarial among wholesalers, are the major driver of nAT 
sales; however, injectable quinine (the recommended treatment for severe and complicated malaria) also 
forms a significant component of nAT sales. 
 
Volumes of AMTs and RDTs sold are low, but persist despite the ban on their sale:  Despite availability in 
more than half of all wholesalers identified, the median volume of AMT sold the week preceding the survey 
among all wholesalers identified was low (0 AETDs).  Even among just those wholesalers with AMTs in stock 
at the time of interview, the volume of AMTs sold (7.9 AETDs) was comparatively lower than those for ACTs 
and nATs.  As for RDTs, even among those wholesalers who had RDTs in stock at the time of interview, the 
median number of RDTs sold in the week preceding the interview was 0 tests; however there was a wide 
variation in the volumes sold (IQR of 0 to 250 tests). 
 
Price Mark-ups 
Wholesaler mark-ups were lower than retailer mark-ups:  Among wholesalers, the median mid percent price 
mark-ups were observed to be fairly consistent across antimalarial categories: 26.7% on ACT, 26.1% on AMT 
and 24.7% on nATs.  Percent price mark-ups were also observed to be consistent across dosage form at 
wholesale level.  The median percent price mark-ups among retailers were not only observed to be 
consistently higher that wholesaler mark-ups, but also varied widely across different retail outlet types and 
dosage forms.  For example, retail mark-ups on ACTs ranged from 42.9% in pharmacies to 200.0% at drug 
stores, and median percent mark-ups greater than 100% were commonly observed in private health 
facilities, drug stores and grocery stores.  In absolute terms, wholesaler mark-ups also tended to be lower 
than retailer mark-ups.  Among wholesalers, median absolute mid mark-ups were US$ 1.58 on ACT, US$ 2.20 
on AMT and US$ 0.14 on nAT; while at retail level, mark-ups ranged between US$ 1.40-4.12 on ACTs, US$ 
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1.50-25.16 on AMT and US$ 0.17-0.67 on nATs.  These higher mark-ups at retail level could be due to a 
variety of reasons.  In private health facilities, higher margins may be required to absorb the costs of other 
services rendered to clientele, such as diagnosis.  In drug stores and grocery stores, larger percent mark-ups 
may reflect their greater tendency to sell a product mix favouring relatively cheaper products compared to 
those sold by pharmacies and private health facilities, such as tablets rather than oral liquids, older nATs 
(e.g. SP) rather than ‘premium priced’ products (i.e. products strategically priced toward the high end of the 
price range to attract status-conscious consumers; an example is halofantrine), or generics rather than 
innovator products.  
 
Large disparities in price and mark-up between AL and SP:  Retailers reported having purchased AL from 
wholesalers at a median price that ranged from US$ 0.94-5.62; while the median purchase price for SP, the 
most commonly cited top selling product, ranged from US$ 0.12 to US$ 0.19.  Among wholesalers, the 
median purchase price for AL was US$ 5.29 compared to a median purchase price for SP of US$ 0.14.  This 
large difference in purchase price is reflected in the higher percent mark-ups added by retailers to SP, which 
ranged from 114-150% across all retail outlet categories.  Although the absolute mark-up gained from each 
AETD of SP sold is small in comparison to AL (US$0.17-0.28 for SP vs. US$ 1.40-4.31), it is likely that the 
continued popularity of SP still makes the sale of this product fairly lucrative.  As SP continues to be the 
recommended antimalarial for the treatment of pregnant women and uncomplicated cases among children 
less than 5kg in weight, demand for this product is likely to continue. 
 
Conclusion 
This report presents a number of important new insights into the market for antimalarial drugs in Zambia.  
The distribution chain had a pyramid shape, with a relatively broad base and narrow top.  While we 
observed wholesalers to operate over 4 overlapping levels, all wholesalers identified were observed to 
supply retailers directly and a high proportion of wholesalers (42%) identified a manufacturer as one of their 
top antimalarial suppliers.  As such, it is likely that most antimalarials in the private sector pass through a 2- 
or 3-step supply chain between manufacturer to retailer.  ACTs, and in particular artemether-lumefantrine, 
the recommended first-line treatment for uncomplicated malaria, were observed to be available in about 
70% of wholesalers; however, wholesale purchase prices for ACTs are high and are many times more 
expensive than other common antimalarials, such as SP.  This may have contributed to our observation that 
SP was the most commonly reported top-selling antimalarial by wholesalers (50%), while only 28% of 
wholesalers reported AL as their top-selling antimalarial.  With respect to oral AMTs, despite the ban on 
their sale since 2003, one third (33%) of all wholesalers continued to stock oral AMTs; however, their sales 
volumes during the week prior to the survey were observed to be very low.  Wholesale percent mark-ups 
were observed to be consistent both across antimalarial categories and across dosage forms, and tended to 
be lower than retail-level percent mark-ups on antimalarials. For RDTs, their wholesale purchase prices were 
also high and they were not widely available among wholesalers.  
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6. Appendices 
6.1. Range of health and non‐health retail outlets selling pharmaceutical drugs in 
Zambia 
Outlet Type N Description 
Public Health Facility 202  
Third-level hospital 7 These are government health facilities providing free prescription medicine, 
medical consultations, and diagnosis.  Health centres serve a catchment area 
of between 10,000 (rural) to 50,000 (urban) residents.  They are staffed by a 
nurse or clinical officer.  First-level hospitals accept referrals from local 
health centres and health posts.  They serve populations of between 80,000 
and 200,000 people with surgical, obstetric and diagnostic services.  At the 
provincial level, second-level hospitals typically offer services in internal 
medicine, gynaecology, psychiatry and intensive care.  Third-level hospitals 
serve a catchment of 800,000 people and expand upon provincial level 
services, while also serving as training and research institutions. 
Second-level hospital (Provincial 
level) 
5 
First-level hospital (District-level) 20 
Hospital affiliated centre 3 
Urban health centre 76 
Rural health centre 76 
Health post 15 
Part One Pharmacy 56  
Part One pharmacy 56 
Pharmacies that are licensed by the Pharmaceutical Regulatory Authority 
(PRA) and sell prescription medicine at a commercial rate.  Part One 
pharmacies are manned by pharmacists and qualified health practitioners.  
They sell all classes of medicines.  In addition to being regulated by the PRA, 
they are also required to have a trading license from the local council.  These 
pharmacies may also sell cosmetics. 
Drug Store 202  
Drug store 202 
Drug stores sells medicines at a commercial rate, but differ from pharmacies 
in a number of aspects:  1) Drug stores are usually smaller than pharmacies; 
2) they are not regulated by the Pharmaceutical Regulatory Authority, and 
instead are licensed by the local government board (however, an unknown 
proportion operate without a license); 3) they are only permitted to sell over 
the counter medicines; 4) they are not guaranteed to be manned by qualified 
health dispensers/ practitioners, and are sometimes manned by relatives of 
qualified health dispensers or someone with only basic education or 
knowledge about medicines. 
Private Health Facility 48  
Private hospitals 4 
Private hospitals sell medicines at a commercial rate and are manned by 
qualified health dispensers/practitioners, who are registered with the 
medical council. These facilities are regulated by the Pharmaceutical 
Regulatory Authority. They have a hospital license and can admit patients for 
more than 48 hours. 
Private clinic  36 
Private clinics sell medicines at a commercial rate and are manned by 
qualified health dispensers/practitioners, who are registered with the 
medical council.  As with private hospitals, they are regulated by the 
Pharmaceutical Regulatory Authority.  Private clinics have a clinic license, and 
differ from hospitals in that they can admit patients for a maximum of 48 
hours. 
Surgery  8 
Surgeries are also manned by qualified health practitioners who are 
registered with the medical council.  They have a clinic license and offer 
certain specialized services, but they are not allowed to admit patients.  They 
are most common in urban areas. 
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Grocery Store 2,236  
Grocery store 2,236 
Small businesses that sell fast moving consumer goods including food, 
beverages, and household products. These outlets commonly sell 
antipyretics. 
Other Outlet 1,096  
Kiosk 23 
Small businesses, made from temporary wooden structures, which sell fast 
moving consumer goods. They may also sell medicines. Kiosks are usually 
found near schools, colleges and universities. 
Kantemba 982 
These are similar to kiosks but have a more permanent structure. They are 
twice the size of a phone booth with walls made from metal. 
Super/Mini market or Petrol 
station 
44 
Express stores at filling stations. Small businesses which sell general 
groceries; they may stock some medicines such as such as antipyretics or 
cough syrups. 
Container 37 
This is a shipment container that has been turned into a shop. They have 
commodities that can also be found in grocery stores but may also sell over 
the counter medicines. Containers need to obtain a trading license from the 
local council. 
Mobile provider 5 
These are street hawkers who sell a variety of items, which may include 
medicines. They typically operate in residential areas and at road junctions. 
In residential zones, hawkers mostly target low income and rural areas. In 
urban zones, they may have a hawker’s license under the local council. 
Pharmacy/Chemist (not 
registered) 
2  
Other 3 
Other outlet types that did not fit into any of the aforementioned outlet 
types. These were largely market stands and stalls.  
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6.2. Calculating AETDs:  antimalarial treatment and equivalent adult treatment dose 
Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Amodiaquine 1800mg   WHO Use of Antimalarials, 2001 
Amodiaquine-Sulfadoxine-
Pyrimethamine 
1800mg Amodiaquine  WHO Model Formulary, 2008 
Arteether 1050mg   WHO Use of Antimalarials, 2001 
Artemether 960mg   WHO Use of Antimalarials, 2001 
Artemether-Lumefantrine 480mg Artemether  WHO Model Formulary, 2008 
Artemisinin-Naphthoquine 2400mg Artemisinin Manufacturer Guidelines for this product 
are 1000mg Artemisinin in a single dose. 
Such a short ACT regimen is highly suspect. 
This treatment dose is based upon the WHO 
Artemisinin-MQ recommendation of a total 
dose of 40mg/kg. 
WHO Use of Antimalarials, 2001 
Artemisinin-Piperaquine 576mg Artemisinin Treatment dose based on Artemisinin-
Piperaquine-Primaquine value, below. 
As below 
Artemisinin-Piperaquine-
Primaquine 
576mg Artemisinin  Tangpukdee, N. et al. 2008. Efficacy of 
Artequick versus artesunate-mefloquine in 
the treatment of acute uncomplicated 
falciparum malaria in Thailand. The 
Southeast Asian Journal of Tropical 
Medicine and Public Health. 39(1): 1-8 
http://imsear.hellis.org/handle/12345678
9/33676  
Artesunate 960mg   WHO Use of Antimalarials, 2001 
Artesunate-Amodiaquine 600mg Artesunate  Manufacturer Guidelines 
(Winthrop/Coarsucam – Sanofi Aventis) 
Artesunate-Halofantrine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
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Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Artesunate-Lumefantrine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
Artesunate-Mefloquine 600mg Artesunate  Manufacturer Guidelines 
(Artequin Adult – Mepha) 
Artesunate-Piperaquine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
Artesunate-Pyronaridine 600mg Artesunate Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the Artesunate-
Amodiaquine, Artesunate-SP, and 
Artesunate-Mefloquine values. 
- 
Artesunate-Sulfadoxine-
Pyrimethamine 
600mg Artesunate  Manufacturer Guidelines 
(Co-arinate – Dafra) 
Atovaquone-Proguanil 3000mg Atovaquone  Manufacturer Guidelines 
(Malanil – GSK) 
Chloroquine 1500mg   WHO Model Formulary, 2008 
Chloroquine-Sulfadoxine-
Pyrimethamine 
1500mg Chloroquine  WHO Model Formulary, 2008 
Chlorproguanil-Dapsone 360mg Chlorproguanil  Manufacturer Guidelines 
(LapDap – GSK) 
Dihydroartemisinin 480mg   Manufacturer Guidelines 
(Cotecxin – Holleypharm; MALUether – 
Euromedi) 
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Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Dihydroartemisinin-
Amodiaquine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Halofantrine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Lumefantrine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Piperaquine 
360mg Dihydroartemisinin  Manufacturer Guidelines 
(Duo-cotecxin – Holleypharm) 
Dihydroartemisinin-
Piperaquine-Trimethoprim 
256mg Dihydroartemisinin  Manufacturer Guidelines 
(Artecxin – Medicare Pharma; Artecom – 
Ctonghe) 
Dihydroartemisinin-
Pyronaridine 
360mg Dihydroartemisinin Relatively uncommon combination; dosing 
information is difficult to find and the value 
here is based on the most common 
Dihydroartemisinin-combinations with 
sources listed below. 
- 
Dihydroartemisinin-
Sulfadoxine-Pyrimethamine 
360mg Dihydroartemisinin  Manufacturer Guidelines 
(Dalasin – Adams Pharma) 
Dihydroartemisinin-
Mefloquine 
360mg Dihydroartemisinin  Manufacturer Guidelines 
(Meflodisin – Adams Pharma) 
Halofantrine 1500mg  This dose is for halofantrine hydrochloride 
as the strength is normally reported in this 
manner. The total dose for halofantrine 
base is 1398 mg. 
Manufacturer Guidelines 
(Halfan – GSK) 
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Antimalarial Category Dose used for 
calculating 
1 AETD 
(mg to treat a 
60kg adult) 
Generic product 
used for AETD mg 
dose value for 
combination 
therapies 
Notes Source 
Hydroxychloroquine 2000mg   Manufacturer Guidelines 
(Plaquenil – Sanofi Aventis) 
Mefloquine 1000mg   WHO Use of Antimalarials, 2001 
Mefloquine-Sulfadoxine-
Pyrimethamine 
1000mg Mefloquine  WHO Use of Antimalarials, 2001 
Primaquine 45mg  This dose is for the gametocytocidal 
treatment of P. falciparum. 
WHO Model Formulary, 2008 
Quinacrine 2212mg  Recommendations for malaria treatment 
are very dated. This value is the treatment 
regimen for giardiasis, which has also been 
used in the treatment for malaria.  
Gardner, T. B. and Hill, D. R. 2001. 
Treatment of Giardiasis. Clinical 
Microbiology Reviews. 14(1): 114-128 
http://cmr.asm.org/cgi/content/full/14/1/
114#T2  
Quinimax 10500mg   Manufacturer Guidelines 
(Quinimax – Sanofi Aventis) 
Quinine 12600mg  This dose is for quinine sulphate, a salt, as 
quinine strengths are normally reported for 
salts. 
The total dose for quinine base based on 
24mg/kg is 10080mg for a 60kg adult. 
WHO Model Formulary, 2008 
Quinine-Sulfadoxine-
Pyrimethamine 
12600mg Quinine This dose is for quinine sulphate, a salt, as 
quinine strengths are normally reported for 
salts. 
The total dose for quinine base based on 
24mg/kg is 10080mg for a 60kg adult. 
WHO Model Formulary, 2008 
Sulfadoxine-Pyrimethamine 1500mg Sulfadoxine  WHO Model Formulary, 2008 
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6.3. Rationale and method of calculating weights and how to use weights to 
calculate indicators 
Weights were calculated differently for PHFs, POPs, and other outlet types, and were specific to analysis 
type, but generally involved the inverse of the selection probability and corresponding population size. We 
used sub-district populations for non-PHFs non-POPs, and for analysis involving only the non-booster sample 
(i.e. estimation of volumes for all outlet types). District populations were used for PHF and POP outlet types 
where analysis included the booster sample (i.e. availability and price). 
 
A correction factor was included in the weighting formula for booster outlets.  This allows us to account for 
potentially different approaches taken to reach outlets in the larger geographical booster areas, and the 
knowledge that a full census was not conducted for all districts and specifically for the registered 
pharmacies.  
 
Weights were not scaled. This was partly for convenience, but also driven by the key indicators being 
proportions and medians, which are invariant under scaling. In analysis the weights indicate the probability 
of selection, and are invoked using the pweight option in Stata commands.  The weight calculations are 
summarized as follows:  
 
Availability and Price analysis: 
i. All PHFs enumerated in a district;  
 
district in the  visitedPHFs ofNumber 
districtfor  frame samplein  listed PHFs ofNumber 
PopulationDistrict   stratumin   visiteddistricts ofNumber 
Population Stratum


iWeight
 
 
where the number of districts visited is 10 for urban and 17 for rural. 
ii. All POPs enumerated in a district; 
 
district in the  visitedPOPs ofNumber 
districtfor  frame samplein  listed POPs ofNumber 
PopulationDistrict   stratumin   visiteddistricts ofNumber 
Population Stratum


iWeight
 
 
where the number of districts visited is 13 for urban and 17 for rural. Note that this differs from those 
values used in equation ii., reflecting the fact that districts outside those containing selected sub-
districts were enumerated for POPs. 
iii. Non-PHF non-POP outlets enumerated in a selected sub-district; 
 
ont PopulatiSubDistric19
ulationStrata Pop

iWeight  
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Volumes analysis (restricted to the non-booster sample): 
i. All outlets enumerated in a selected sub-district; 
 
Populationt SubDistric19
Population Strata

iWeight
 
 
Data provided for weight estimation 
i. Population size at sub-district level (projections for 2008) (Ref: Final Sampling Frame 2000 Zambia, 
Central Statistical Office, Lusaka, Zambia. Unpublished) 
ii. A list of the selected sub-districts in the two strata: urban and rural 
iii. List of PHFs at district level (Ref: Health Institutions in Zambia, Zambia MoH,  2008) 
iv. List of registered pharmacies (POPs) by district, dated April 2009 (Ref: List of licensed pharmaceutical 
retail outlets as at April 2009, Pharmaceutical Regulatory Authority (MoH), Zambia) 
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